US20110223257A1 - Releasable fusogenic lipids for nucleic acids delivery systems - Google Patents

Releasable fusogenic lipids for nucleic acids delivery systems Download PDF

Info

Publication number
US20110223257A1
US20110223257A1 US13/129,546 US200913129546A US2011223257A1 US 20110223257 A1 US20110223257 A1 US 20110223257A1 US 200913129546 A US200913129546 A US 200913129546A US 2011223257 A1 US2011223257 A1 US 2011223257A1
Authority
US
United States
Prior art keywords
substituted
nhc
alkyl
nanoparticle
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/129,546
Other languages
English (en)
Inventor
Hong Zhao
Weili Yan
Lianjun Shi
Dechun Wu
Maksim Royzen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Belrose Pharma Inc
Original Assignee
Enzon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzon Pharmaceuticals Inc filed Critical Enzon Pharmaceuticals Inc
Priority to US13/129,546 priority Critical patent/US20110223257A1/en
Assigned to ENZON PHARMACEUTICALS, INC. reassignment ENZON PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SHI, LIANJUN, YAN, WEILI, WU, DECHUN, ZHAO, HONG, ROYZEN, MAKSIM
Publication of US20110223257A1 publication Critical patent/US20110223257A1/en
Assigned to ENZON PHARMACEUTICALS, INC. reassignment ENZON PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ROYZEN, MAKSIM, WU, DECHUN, ZHAO, HONG, SHI, LIANJUN, YAN, WEILI
Assigned to BELROSE PHARMA, INC. reassignment BELROSE PHARMA, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ENZON PHARMACEUTICALS, INC.
Assigned to BELROSE PHARMA INC. reassignment BELROSE PHARMA INC. CHANGE OF ADDRESS Assignors: BELROSE PHARMA INC.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • oligonucleotides do not effectively deliver oligonucleotides into the body, although some progress has been made in the delivery of plasmids.
  • desirable delivery systems should include positive charges sufficient enough to neutralize the negative charges of oligonucleotides.
  • coated cationic liposomal (CCL) and Stable Nucleic Acid-Lipid Particles (SNALP) formulations described by Stuart, D. D., et al Biochim. Biophys. Acta, 2000, 1463:219-229 and Semple, S. C., et al, Biochim. Biophys. Acta, 2001, 1510:152-166, respectively, were reported to provide nanoparticles with small sizes, high nucleic acid encapsulation rate, good serum stability, and long circulation time.
  • the present invention provides releasable fusogenic lipids containing an imine linker and a zwitterionic moiety, and nanoparticle compositions containing the same for nucleic acids delivery.
  • Polynucleic acids such as oligonucleotides, are encapsulated within nanoparticle complexes containing a mixture of a cationic lipid, a releasable fusogenic lipid described herein, and a PEG lipid.
  • the releasable fusogenic lipids for the delivery of nucleic acids i.e., an oligonucleotide
  • nucleic acids i.e., an oligonucleotide
  • R is a water soluble neutral charged or zwitterion-containing moiety
  • L 1-2 are independently selected bifunctional linkers
  • M is an imine-containing moiety
  • Q is a substituted or unsubstituted, saturated or unsaturated C4-30-containing moiety
  • (b) is 0 or a positive integer.
  • the present invention also provides nanoparticle compositions for nucleic acids delivery.
  • the nanoparticle composition for the delivery of nucleic acids i.e., an oligonucleotide
  • the nanoparticle composition for the delivery of nucleic acids can include:
  • nucleic acids preferably oligonucleotides
  • oligonucleotides introduced by the methods described herein can modulate expression of a target gene.
  • Another aspect of the present invention provides methods of inhibiting expression of a target gene, i.e., oncogenes and genes associated with disease in mammals, preferably humans.
  • the methods include contacting cells, such as cancer cells or tissues, with a nanoparticle/nanoparticle complex prepared from the nanoparticle composition described herein.
  • the oligonucleotides encapsulated within the nanoparticle are released, which then mediate the down-regulation of mRNA or protein in the cells or tissues being treated.
  • the treatment with the nanoparticle allows modulation of target gene expression (and the attendant benefits associated therewith) in the treatment of malignant disease, such as inhibition of the growth of cancer cells.
  • Such therapies can be carried out as a single treatment or as part of a combination therapy, with one or more useful and/or approved treatments.
  • Further aspects include methods of making the compounds of Formula (I) as well as nanoparticles containing the same.
  • nanoparticle composition containing a releasable fusogenic lipid described herein provides a means for in vivo as well as in vitro administration of nucleic acids.
  • the nanoparticles containing the releasable fusogenic lipids described herein can help release nucleic acids encapsulated therein when the nanoparticles enter the cells and cellular compartments. Without being bound by any theory, such feature is attributed in part to the acid labile linker.
  • the imine-based linkers are acid-labile and hydrolyzed in acidic environment such is as cancer cells and endosome. Thus, the imine-based linkers can facilitate disruption of the nanoparticles, thereby allowing intracellular release of nucleic acids.
  • the releasable fusogenic lipids containing zwitterionic charged groups enhance cellular uptake of nucleic acids.
  • the polar but neutrally charged groups facilitate the nanoparticles to cross the cellular membrane.
  • the releasable fusogenic lipids described herein stabilize nanoparticle complexes and nucleic acids therein in biological fluids.
  • the nanoparticle complexes can shield nucleic acids molecules from nucleases, thereby protecting the polynucleic acids from degradation.
  • the nanoparticle delivery systems described herein allow sufficient amounts of the therapeutic oligonucleotides to be selectively available at the desired target area, such as cancer cells via EPR (Enhanced Permeation and Retention) effects.
  • the therapeutic nucleic acids at the target area can modulate expression of a target gene specifically in cancer cells or tissues.
  • nanoparticles described herein can also be used in the delivery of biologically active molecules, such as small molecule chemotherapeutics as well as one or more different types of therapeutic nucleic acids, thereby attaining synergistic effects in the treatment of disease.
  • the term “residue” shall be understood to mean that portion of a compound, to which it refers, e.g., C6-30 hydrocarbons, etc. that remains after it has undergone a substitution reaction with another compound.
  • alkyl refers to a saturated aliphatic hydrocarbon, including straight-chain, branched-chain, and cyclic alkyl groups.
  • alkyl also includes alkyl-thio-alkyl, alkoxyalkyl, cycloalkylalkyl, heterocycloalkyl, and C 1-6 alkylcarbonylalkyl groups.
  • the alkyl group has 1 to 12 carbons. More preferably, it is a lower alkyl of from about 1 to 7 carbons, yet more preferably about 1 to 4 carbons.
  • the alkyl group can be substituted or unsubstituted.
  • the substituted group(s) preferably include halo, oxy, azido, nitro, cyano, alkyl, alkoxy, alkyl-thio, alkyl, alkoxyalkyl, alkylamino, trihalomethyl, hydroxyl, mercapto, hydroxy, cyano, alkylsilyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl, alkenyl, alkynyl, C 1-6 hydrocarbonyl, aryl, and amino groups.
  • substituted refers to adding or replacing one or more atoms contained within a functional group or compound with one of the moieties from the group of halo, oxy, azido, nitro, cyano, alkyl, alkoxy, alkyl-thio-alkyl, alkoxyalkyl, alkylamino, trihalomethyl, hydroxyl, mercapto, hydroxy, cyano, alkylsilyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl, alkenyl, alkynyl, C 1-6 alkylcarbonylalkyl, aryl, and amino groups.
  • alkenyl refers to groups containing at least one carbon-carbon double bond, including straight-chain, branched-chain, and cyclic groups.
  • the alkenyl group has about 2 to 12 carbons. More preferably, it is a lower alkenyl of from about 2 to 7 carbons, yet more preferably about 2 to 4 carbons.
  • the alkenyl group can be substituted or unsubstituted.
  • the substituted group(s) preferably include halo, oxy, azido, nitro, cyano, alkyl, alkoxy, alkyl-thio-alkyl, alkoxyalkyl, alkylamino, trihalomethyl, hydroxyl, mercapto, hydroxy, cyano, alkylsilyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl, alkenyl, alkynyl, C 1-6 hydrocarbonyl, aryl, and amino groups.
  • alkynyl refers to groups containing at least one carbon-carbon triple bond, including straight-chain, branched-chain, and cyclic groups.
  • the alkynyl group has about 2 to 12 carbons. More preferably, it is a lower alkynyl of from about 2 to 7 carbons, yet more preferably about 2 to 4 carbons.
  • the alkynyl group can be substituted or unsubstituted.
  • the substituted group(s) preferably include halo, oxy, azido, nitro, cyano, alkyl, alkoxy, alkyl-thio-alkyl, alkoxyalkyl, alkylamino, trihalomethyl, hydroxyl, mercapto, hydroxy, cyano, alkylsilyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl, alkenyl, alkynyl, C 1-6 hydrocarbonyl, aryl, and amino groups.
  • alkynyl include propargyl, propyne, and 3-hexyne.
  • aryl refers to an aromatic hydrocarbon ring system containing at least one aromatic ring.
  • the aromatic ring can optionally be fused or otherwise attached to other aromatic hydrocarbon rings or non-aromatic hydrocarbon rings.
  • aryl groups include, for example, phenyl, naphthyl, 1,2,3,4-tetrahydronaphthalene and biphenyl.
  • Preferred examples of aryl groups include phenyl and naphthyl.
  • cycloalkyl refers to a C 3-8 cyclic hydrocarbon. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
  • cycloalkenyl refers to a C 3-8 cyclic hydrocarbon containing at least one carbon-carbon double bond.
  • examples of cycloalkenyl include cyclopentenyl, cyclopentadienyl, cyclohexenyl, 1,3-cyclohexadienyl, cycloheptenyl, cycloheptatrienyl, and cyclooctenyl.
  • cycloalkylalkyl refers to an alklyl group substituted with a C 3-8 cycloalkyl group.
  • examples of cycloalkylalkyl groups include cyclopropylmethyl and cyclopentylethyl.
  • alkoxy refers to an alkyl group of indicated number of carbon atoms attached to the parent molecular moiety through an oxygen bridge.
  • alkoxy groups include, for example, methoxy, ethoxy, propoxy and isopropoxy.
  • an “alkylaryl” group refers to an aryl group substituted with an alkyl group.
  • an “aralkyl” group refers to an alkyl group substituted with an aryl group.
  • alkoxyalkyl group refers to an alkyl group substituted with an alkloxy group.
  • alkyl-thio-alkyl refers to an alkyl-S-alkyl thioether, for example methylthiomethyl or methylthioethyl.
  • amino refers to a nitrogen containing group as is known in the art derived from ammonia by the replacement of one or more hydrogen radicals by organic radicals.
  • acylamino and alkylamino refer to specific N-substituted organic radicals with acyl and alkyl substituent groups respectively.
  • alkylcarbonyl refers to a carbonyl group substituted with alkyl group.
  • halogen' or halo refers to fluorine, chlorine, bromine, and iodine.
  • heterocycloalkyl refers to a non-aromatic ring system containing at least one heteroatom selected from nitrogen, oxygen, and sulfur.
  • the heterocycloalkyl ring can be optionally fused to or otherwise attached to other heterocycloalkyl rings and/or non-aromatic hydrocarbon rings.
  • Preferred heterocycloalkyl groups have from 3 to 7 members. Examples of heterocycloalkyl groups include, for example, piperazine, morpholine, piperidine, tetrahydrofuran, pyrrolidine, and pyrazole.
  • Preferred heterocycloalkyl groups include piperidinyl, piperazinyl, morpholinyl, and pyrrolidinyl.
  • heteroaryl refers to an aromatic ring system containing at least one hetero atom selected from nitrogen, oxygen, and sulfur.
  • the heteroaryl ring can be fused or otherwise attached to one or more heteroaryl rings, aromatic or non-aromatic hydrocarbon rings or heterocycloalkyl rings.
  • heteroaryl groups include, for example, pyridine, furan, thiophene, 5,6,7,8-tetrahydroisoquinoline and pyrimidine.
  • heteroaryl groups include thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, benzimidazolyl, furanyl, benzofuranyl, thiazolyl, benzothiazolyl, isoxazolyl, oxadiazolyl, isothiazolyl, benzisothiazolyl, triazolyl, tetrazolyl, pyrrolyl, indolyl, pyrazolyl, and benzopyrazolyl.
  • heteroatom refers to nitrogen, oxygen, and sulfur.
  • substituted alkyls include carboxyalkyls, aminoalkyls, dialkylaminos, hydroxyalkyls and mercaptoalkyls; substituted alkenyls include carboxyalkenyls, aminoalkenyls, dialkenylaminos, hydroxyalkenyls and mercaptoalkenyls; substituted alkynyls include carboxyalkynyls, aminoalkynyls, dialkynylaminos, hydroxyalkynyls and mercaptoalkynyls; substituted cycloalkyls include moieties such as 4-chlorocyclohexyl; aryls include moieties such as napthyl; substituted aryls include moieties such as 3-bromo phenyl; aralkyls include moieties such as tolyl; heteroalkyls include moieties such as ethylthiophene; substituted heteroalryls include
  • positive integer shall be understood to include an integer equal to or greater than I and as will be understood by those of ordinary skill to be within the realm of reasonableness by the artisan of ordinary skill.
  • the term “linked” shall be understood to include covalent (preferably) or noncovalent attachment of one group to another, i.e., as a result of a chemical reaction.
  • nanoparticle and/or “nanoparticle complex” formed using the nanoparticle composition described herein refers to a lipid-based nanocomplex.
  • the nanoparticle contains nucleic acids such as oligonucleotides encapsulated in a mixture of a cationic lipid, a fusogenic lipid, and a PEG lipid. Alternatively, the nanoparticle can be formed without nucleic acids.
  • therapeutic oligonucleotide refers to an oligonucleotide used as a pharmaceutical or diagnostic agent.
  • modulation of gene expression shall be understood as broadly including down-regulation or up-regulation of any types of genes, preferably associated with cancer and inflammation, compared to a gene expression observed in the absence of the treatment with the nanoparticle described herein, regardless of the route of administration.
  • inhibition of expression of a target gene shall be understood to mean that mRNA expression or the amount of protein translated are reduced or attenuated when compared to that observed in the absence of the treatment with the nanoparticle described herein.
  • Suitable assays of such inhibition include, e.g., examination of protein or mRNA levels using techniques known to those of skill in the art such as dot blots, northern blots, in situ hybridization, ELISA, immunoprecipitation, enzyme function, as well as phenotypic assays known to those of skill in the art.
  • the treated conditions can be confirmed by, for example, decrease in mRNA levels in cells, preferably cancer cells or tissues.
  • successful inhibition or treatment shall be deemed to occur when the desired response is obtained.
  • successful inhibition or treatment can be defined by obtaining e.g, 10% or higher (i.e. 20% 30%, 40%) down regulation of genes associated with tumor growth inhibition.
  • successful treatment can be defined by obtaining at least 20% or preferably 30%, more preferably 40% or higher (i.e., 50% or 80%) decrease in oncogene mRNA levels in cancer cells or tissues, including other clinical markers contemplated by the artisan in the field, when compared to that observed in the absence of the treatment with the nanoparticle described herein.
  • compositions comprising an oligonucleotide, a cholesterol analog, a cationic lipid, a releasable fusogenic lipid, a PEG lipid etc. refers to one or more molecules of that oligonucleotide, cholesterol analog, cationic lipid, releasable fuosogenic lipid, PEG lipid, etc. It is also contemplated that the oligonucleotide can be the same or different kind of gene. It is also to be understood that this invention is not limited to the particular configurations, process steps, and materials disclosed herein as such configurations, process steps, and materials may vary somewhat.
  • FIG. 1 schematically illustrates a reaction scheme for preparing compound 6, as described in Examples 6-11.
  • FIG. 2 schematically illustrates a reaction scheme for preparing compound 10, as described in Examples 12-15.
  • R is a water soluble neutral charged or zwitterion-containing moiety
  • L 1-2 are independently selected bifunctional linkers
  • M is an imine-containing moiety
  • Q is a substituted or unsubstituted, saturated or unsaturated C4-30-containing moiety
  • (a) is 0 or a positive integer, preferably zero or an integer of from about 1 to about 10 (e.g., 1, 2, 3, 4, 5, 6);
  • (b) is 0 or a positive integer, preferably zero or an integer of from about 1 to about 10 (e.g., 1, 2, 3, 4, 5, 6).
  • L 1 and L 2 are independently the same or different when (a) and (b) are equal to or greater than 2.
  • the compounds of Formula described herein include the Q hydrocarbon group (aliphatic).
  • the Q group has Formula (Ia):
  • Y 1 and Y′ 1 are independently O, S or NR 4 , preferably oxygen;
  • (d) is 0 or a positive integer, preferably zero or an integer of from about 1 to about 10 (e.g., 1, 2, 3, 4, 5, 6);
  • X is C, N or P
  • Q 1 is H, C 1-3 alkyl, NR 5 , OH, or
  • Q 2 is H, C 1-3 alkyl, NR 6 , OH, or
  • Q 3 is a lone electron pair, ( ⁇ O), H, C 1-3 alkyl, NR 7 , OH, or
  • R 2-3 are independently selected from the group consisting of hydrogen, hydroxyl, amine, substituted amine, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-19 branched alkyl, C 3-8 cycloalkyl, C 1-6 substituted alkyl, C 2-6 substituted alkenyl, C 2-6 substituted alkynyl, C 3-8 substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, C 1-6 heteroalkyl, and substituted C 1-6 heteroalkyl, preferably, hydrogen, hydroxyl, amine, methyl, ethyl and propyl; and
  • R 4-8 are independently selected from the group consisting of hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-19 branched alkyl, C 3-8 cycloalkyl, C 1-6 substituted alkyl, C 2-6 substituted alkenyl, C 2-6 substituted alkynyl, C 3-8 substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, C 1-6 heteroalkyl, and substituted C 1-6 heteroalkyl, preferably, hydrogen, methyl, ethyl and propyl,
  • Q includes at least one or two (e.g., one, two, three) of R 11 , R 12 and R 13 .
  • combinations of the bifunctional linkers and the bifunctional spacers contemplated within the scope of the present invention include those in which combinations of variables and substituents of the linker and spacer groups are permissible so that such combinations result in stable compounds of Formula (I).
  • the combinations of values and substituents do not permit oxygen, nitrogen or carbonyl to be positioned directly adjacent to imine.
  • Q includes at least two of R 11 , R 12 and R 13 .
  • the —C(R 2 R 3 )— group, in each occurrence is the same or different when (d) is equal to or greater than 2.
  • the imine-containing moiety has the formula:
  • R 1 is hydrogen, C 1-6 alkyl, C 3-8 branched alkyl, C 3-8 cycloalkyl, C 1-6 substituted alkyl, C 3-8 substituted cycloalkyl, aryl and substituted aryl, preferably, hydrogen, methyl, ethyl, or propyl.
  • the acid-labile M linker is —N ⁇ CH— or —CH ⁇ N—.
  • the releasable fusogenic lipids described herein have Formula (Ib) or (I′b):
  • the compounds described herein include a terminal zwitterion.
  • the zwitterion includes an amine and an acid.
  • the acidic proton is positioned three to eight atoms from the amine (e.g., the acidic proton is positioned 3, 4, 5, 6, 7, or 8 atoms from the amine).
  • the acidic proton is positioned three to six atoms from the amine.
  • the acid includes, but is not limited to, a carboxylic acid, a sulfonic acid, or a phosphoric acid.
  • the zwitterion-containing moiety is a zwitterionic form of an amino acid.
  • R group include, but are not limited to:
  • Lys —HN—(CH 2 ) 4 CH(COO)(NH 3 ),
  • the zwitterion-containing moiety is a derivative of zwitterionic form of an amino acid.
  • the amino acid can be naturally-occurring amino acids or derivatives of the naturally occurring amino acids.
  • amino acid analogs and derivates include: 2-aminoadipic acid, 3-aminoadipic acid, beta-alanine, beta-aminopropionic acid, 2-aminobutyric acid, 4-aminobutyric acid, piperidinic acid, 6-aminocaproic acid, 2-aminoheptanoic acid, 2-aminoisobutyric acid, 3-aminoisobutyric acid, 2-aminopimelic acid, 2,4-aminobutyric acid, desmosine, 2,2-diaminopimelic acid, 2,3-diaminopropionic acid, N-ethyl glycine, N-ethylasparagine, 3-hydroxyproline, 4-hydroxyproline, isodesmosine, allo-isoleucine, N-
  • the L 1 group as included in the compounds of Formula (I) is selected from among:
  • Y 16 is O, NR 28 , or S, preferably oxygen
  • Y 14-15 and Y 17-19 are independently O, NR 29 , or S, preferably O, or NR 29 ;
  • R 21-27 are independently selected from among hydrogen, hydroxyl, amine, C 1-6 alkyls, C 3-12 branched alkyls, C 3-8 cycloalkyls, C 1-6 substituted alkyls, C 3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C 1-6 heteroalkyls, substituted C 1-6 heteroalkyls, C 1-6 alkoxy, phenoxy and C 1-6 heteroalkoxy, preferably, hydrogen, methyl, ethyl or propyl; and
  • R 28-29 are independently selected from among hydrogen, C 1-6 alkyls, C 3-12 branched alkyls, C 3-8 cycloalkyls, C 1-6 substituted alkyls, C 3-8 , substituted cycloalkyls, aryls, substituted aryls, aralkyls, C 1-6 heteroalkyls, substituted C 1-6 heteroalkyls, C 1-6 alkoxy, phenoxy and C 1-6 heteroalkoxy, preferably, hydrogen, methyl, ethyl or propyl;
  • (t1), (t2), (t3) and (t4) are independently zero or positive integers, preferably zero or a positive integer of from about 1 to about 10 (e.g., 1, 2, 3, 4, 5, 6); and
  • the bifunctional L 1 linkers contemplated within the scope of the present invention include those in which combinations of substituents and variables are permissible so that such combinations result in stable compounds of Formula (I). For example, when (a3) is zero, Y 17 is not linked directly to Y 14 .
  • bifunctional linkers when values for bifunctional linkers are positive integers equal to or greater than 2, the same or different bifunctional linkers can be employed.
  • R 21 -R 28 in each occurrence, are independently the same or different when each of (t1), (t2), (t3) and (t4) is independently equal to or greater than 2.
  • Y 14-15 and Y 17-19 are O or NH; and R 21-29 are independently hydrogen or methyl.
  • Y 16 is O; Y 14-15 and Y 17-19 are O or NH; and R 21-29 are hydrogen.
  • L 1 is independently selected from among:
  • Y 14-15 and Y 17-19 are independently O, or NH;
  • (t1), (t2), (t3), and (t4) are independently zero or positive integers, preferably zero or positive integers of from about 1 to about 10 (e.g., 1, 2, 3, 4, 5, 6); and
  • Y 17 in each occurrence, is the same or different, when (t1) or (t3) is equal to or greater than 2.
  • Y 19 in each occurrence, is the same or different, when (t2) is equal to or greater than 2.
  • illustrative examples of the L 1 group are selected from among:
  • L 2 is independently selected from among:
  • Y′ 16 is O, NR′ 28 , or S, preferably oxygen;
  • Y′ 14-15 and Y′ 17 are independently O, NR′ 29 , or S, preferably O, or NR′ 29 ;
  • R′ 21-27 are independently selected from among hydrogen, hydroxyl, amine, C 1-6 alkyls, C 3-12 branched alkyls, C 3-8 cycloalkyls, C 1-6 substituted alkyls, C 3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C 1-6 heteroalkyls, substituted C 1-6 heteroalkyls, C 1-6 alkoxy, phenoxy and C 1-6 heteroalkoxy, preferably, hydrogen, methyl, ethyl or propyl;
  • R′ 28-29 are independently selected from among hydrogen, C 1-6 alkyls, C 3-12 branched alkyls, C 3-8 cycloalkyls, C 1-6 substituted alkyls, C 3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C 1-6 heteroalkyls, substituted C 1-6 heteroalkyls, C 1-6 alkoxy, phenoxy and C 1-6 heteroalkoxy, preferably, hydrogen, methyl, ethyl or propyl;
  • (t′1), (t′2), (t′3) and (t′4) are independently zero or positive integers, preferably zero or a positive integer of from about 1 to about 10 (e.g., 1, 2, 3, 4, 5, 6); and
  • the bifunctional L 2 linkers contemplated within the scope of the present invention include those in which combinations of variables and substituents of the linkers groups are permissible so that such combinations result in stable compounds of Formula (I). For example, when (a′3) is zero, Y′ 14 is not linked directly to Y′ 14 or Y′ 17 .
  • bifunctional L 2 linkers including releasable linkers are positive integers equal to or greater than 2, the same or different bifunctional linkers can be employed.
  • Y′ 14-15 and Y′ 17 are O or NH; and R′ 21-29 are independently hydrogen or methyl.
  • Y′ 16 is O; Y′ 14-15 and Y′ 17 are O or NH; and R′ 21-29 are hydrogen.
  • L 2 is selected from among:
  • Y′ 14-15 and Y′ 17 are independently O, or NH;
  • (t′1), (t′2), (t′3), and (t′4) are independently zero or positive integers, preferably 0 or positive integers of from about 1 to about 10 (e.g., 1, 2, 3, 4, 5, 6); and
  • Y ′ 14 in each occurrence, is the same or different, when (t′1) or (t′2) is equal to or greater than 2.
  • Y′ 15 in each occurrence, is the same or different, when (t′2) is equal to or greater than 2.
  • illustrative examples of the L 2 group are selected from among:
  • the bifunctional linkers L 1 and L 2 can be a spacer having a substituted saturated or unsaturated, branched or linear, C 3-50 alkyl (i.e., C 3-40 alkyl, C 3-20 alkyl, C 3-15 alkyl, C 3-10 alkyl, etc.), wherein optionally one or more carbons are replaced with NR 6 , O, S or C( ⁇ Y), (preferably O or NH), but not exceeding 70% (i.e., less than 60%, 50%, 40%, 30%, 20%, 10%) of the carbons being replaced.
  • the bifunctional spacers L 11-13 are independently selected from among:
  • Y 26 is O, NR 33 , or S, preferably oxygen or NR 33 ;
  • R 31-32 are independently selected from among hydrogen, hydroxyl, C 1-6 alkyls, C 3-12 branched alkyls, C 3-8 cycloalkyls, C 1-6 substituted alkyls, C 3-8 substituted cycloalkyls, C 1-6 heteroalkyls, substituted C 1-6 heteroalkyls, C 1-6 alkoxy, phenoxy and C 1-6 heteroalkoxy, preferably, hydrogen, methyl, ethyl or propyl;
  • R 33 is selected from among hydrogen, hydroxyl, C 1-6 alkyls, C 3-12 branched alkyls, C 3-8 cycloalkyls, C 1-6 substituted alkyls, C 3-8 substituted cycloalkyls, C 1-6 heteroalkyls, substituted C 1-6 heteroalkyls, C 1-6 alkoxy, phenoxy and C 1-6 heteroalkoxy, preferably, hydrogen, methyl, ethyl or propyl; and
  • (q1) is zero or a positive integer, preferably zero or an integer of from about 1 to about 10 (e.g., 1, 2, 3, 4, 5, 6).
  • bifunctional spacers contemplated within the scope of the present invention include those in which combinations of substituents and variables are permissible so that such combinations result in stable compounds of Formula (I).
  • R 31 and R 32 in each occurrence, are independently the same or different when (q1) is equal to or greater than 2.
  • R′ 31-33 are hydrogen or methyl.
  • R 31-32 are hydrogen or methyl; and Y 26 is O or NH.
  • the C(R 31 )(R 32 ) moiety is the same or different when (q1) is equal to or greater than 2.
  • L 11-13 are independently selected from among:
  • the Q group contains one or more substituted or unsubstituted, saturated or unsaturated C4-30-containing moieties.
  • the Q group includes one or more C4-30 aliphatic saturated or unsaturated hydrocarbons.
  • the Q group is represented by Formula (Ia):
  • X is C, N or P
  • Q 1 is H, C 1-3 alkyl, NR 5 , OH, or
  • Q 2 is H, C 1-3 alkyl, NR 6 , OH, or
  • Q 3 is a lone electron pair, ( ⁇ O), H, C 1-3 alkyl, NR 7 , OH, or
  • L 11 , L 12 and L 13 are independently selected bifunctional spacers
  • Y 11 , Y′ 11 , Y 12 , Y′ 12 , Y 13 , and Y′ 13 are independently O, S or NR 8 ;
  • R 11 , R 12 and R 13 are independently (substituted or unsubstituted) saturated or unsaturated C 4-30 ;
  • Q includes at least one or two of R 11 , R 12 and R 13 .
  • R 11 , R 12 and R 13 independently include a C4-30 saturated or unsaturated aliphatic hydrocarbon. More preferably, each aliphatic hydrocarbon is a saturated or unsaturated C8-24 hydrocarbon (yet more preferably, C12-22 hydrocarbon: C12-22 alkyl, C12-22 alkenyl, C12-22 alkyloxy).
  • aliphatic hydrocarbon examples include, but are not limited to, auroyl (C12), myristoyl (C14), palmitoyl (C16), stearoyl (C18), oleoyl (C18), and erucoyl (C22); saturated or unsaturated C12 alkyloxy, C14 alkyloxy, C16 alkyloxy, C18 alkyloxy, C20 alkyloxy, and C22 alkyloxy; and, saturated or unsaturated C12 alkyl, C14 alkyl, C16 alkyl, C18 alkyl, C20 alkyl, and C22 alkyl,
  • At least two of R 11 , R 12 and R 13 independently include a saturated or unsaturated C8-24 hydrocarbon (more preferably, C12-22 hydrocarbon).
  • Y 1 is O, S, or NR 31 , preferably oxygen or NH;
  • R 11 , R 12 , and R 13 are independently substituted or unsubstituted, saturated or unsaturated C 4-30 (alkyl, alkenyl, alkoxy);
  • R 31 is hydrogen, methyl or ethyl
  • (d) is 0 or a positive integer, preferably 0 or an integer from about”(to about 10 (e.g., 1, 2, 3, 4, 5, 6);
  • the Q group includes diacylglycerol, diacylglycamide, dialkylpropyl, phosphatidylethanolamine or ceramide.
  • Suitable diacylglycerol or diacylglycamide include a dialkylglycerol or dialkylglycamide group having alkyl chain length independently containing from about C 4 to about C 30 , preferably from about C 8 to about C 24 , saturated or unsaturated carbon atoms.
  • the dialkylglycerol or dialkylglycamide group can further include one or more substituted alkyl groups.
  • DAG diacylglycerol
  • R 111 and R 112 fatty acyl chains
  • the R 11 and R 12 have the same or different about 4 to about 30 carbons (preferably about 8 to about 24) and are bonded to glycerol by ester linkages.
  • the acyl groups can be saturated or unsaturated with various degrees of unsaturation.
  • DAG has the general formula:
  • Examples of the DAG can be selected from among a dilaurylglycerol (C12), a dimyristylglycerol (C14, DMG), a dipalmitoylglycerol (C16, DPG), a distearylglycerol (C18, DSG), a dioleoylglycerol (C18), a dierucoyl (C22), a dilaurylglycamide (C12), a dimyristylglycamide (C14), a dipalmitoylglycamide (C16), a disterylglycamide (C18), a dioleoylglycamide (C18), dierucoylglycamide (C22).
  • diacylglycerols are also contemplated.
  • dialkyloxypropyl refers to a compound having two alkyl chains, R 111 and R 112 .
  • the R 111 and R 112 alkyl groups include the same or different between about 4 to about 30 carbons (preferably about 8 to about 24).
  • the alkyl groups can be saturated or have varying degrees of unsaturation.
  • Dialkyloxypropyls have the general formula:
  • R 111 and R 112 alkyl groups are the same or different alkyl groups having from about 4 to about 30 carbons (preferably about 8 to about 24).
  • the alkyl groups can be saturated or unsaturated. Suitable alkyl groups include, but are not limited to, lauryl (C12), myristyl (C14), palmityl (C16), stearyl (C18), oleoyl (C18) and icosyl (C20).
  • R 111 and R 112 are both the same, i.e., R 111 and R 112 are both myristyl (C14) or both oleoyl (C18), etc.
  • R 111 and 8 112 are different, i.e., R 111 is myristyl (C14) and R 112 is stearyl (C18).
  • the Q group can include phosphatidylethanolamines (PE).
  • PE phosphatidylethanolamines
  • the phosphatidylethanolamines useful for the releasable fusogenic lipid conjugation can contain saturated or unsaturated fatty acids with carbon chain lengths in the range of about 4 to about 30 carbons (preferably about 8 to about 24).
  • Suitable phosphatidylethanolamines include, but are not limited to: dimyristoylphosphatidylethanolamine (DMPE), dipalmitoylphosphatidylethanolamine (DPPE), dioleoylphosphatidylethanolamine (DOPE) and distearoylphosphatidylethanolamine (DSPE).
  • the Q group can include ceramides (Cer). Ceramides have only one acyl group. Ceramides can have saturated or unsaturated fatty acids with carbon chain lengths in the range of about 4 to about 30 carbons (preferably about 8 to about 24).
  • R 11 - 13 are independently the same or different C12-22 saturated or unsaturated aliphatic hydrocarbons such as a dilauryl (C12), a dimyristyl (C14), a dipalmitoyl (C16), a distearyl (C18), a dioleoyl (C18), and a dierucoyl (C22);
  • the methods of preparing compound of Formula (I) described herein include reacting an amine-containing compound with an aldehyde-containing compound to provide a fusogenic lipid having an imine moiety.
  • the amine can be a primary amine and the aldehyde can further contains aliphatic or aromatic substituents.
  • lipids are coupled with a nucleophilic multifunctional linker (compound 1) to provide compound 2 in the presence of a coupling agent such as EDC or DIPC.
  • a coupling agent such as EDC or DIPC.
  • the reaction is carried out in an inert solvent such as methylene chloride, chloroform, toluene, DMF or mixtures thereof.
  • the reaction is also preferably conducted in the presence of a base, such as DMAP, DIEA, pyridine, triethylamine, etc. at a temperature of from ⁇ 4° C. to about 70° C. (e.g. ⁇ 4° C. to about 50° C.).
  • the reaction is performed at a temperature from 0° C. to about 25° C. or 0° C. to about room temperature.
  • the terminal functional group of compound 2 is further coupled with a bifunctional linker, such as compound 4, followed by removal of an amine protecting group to provide a lipid compound having a terminal amine (compound 6).
  • a compound containing zwitterionic moieties such as Fmoc-Lys(OMe)-NH 2
  • a bifunctional linker such as compound 7, to provide compound 8 with a protected aldehyde.
  • the aldehyde protecting group is removed.
  • the aldehyde of compound 9 is reacted with an amine-containing lipid (compound 6) under conditions for dehydration, followed by removal of amine protecting group and saponification to provide fusogenic lipids containing an imine bond.
  • Attachment of the lipids to the nucleophilic multifunctional linker can be carried out using standard organic synthetic techniques in the presence of a base, using coupling agents known to those of ordinary skill in the art such as 1,3-diisopropylcarbodiimide (DIPC), dialkyl carbodiimides, 2-halo-1-alkylpyridinium halides, 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide (EDC), propane phosphonic acid cyclic anhydride (PPACA) and phenyl dichlorophosphates.
  • DIPC 1,3-diisopropylcarbodiimide
  • EDC 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide
  • PPACA propane phosphonic acid cyclic anhydride
  • phenyl dichlorophosphates phenyl dichlorophosphates.
  • the formation of imine bond can be carried out using standard organic synthetic techniques
  • an activated lipid acid such as NHS or PNP ester
  • the nucleophile multifunctional linker such as compound 1.
  • lipids are activated with a leaving group such as NHS, or PNP, a coupling agent is not required and the reaction proceeds in the presence of a base.
  • a leaving group such as NHS, or PNP
  • Removal of a protecting group from an amine-containing compound can be carried out with a strong acid such as trifluoroacetic acid (TFA), HCl, sulfuric acid, etc., or catalytic hydrogenation, radical reaction, etc.
  • a strong acid such as trifluoroacetic acid (TFA), HCl, sulfuric acid, etc., or catalytic hydrogenation, radical reaction, etc.
  • removal of an amine-protecting group, such as Fmoc can be carried out with a base such as piperidine or DMAP.
  • the deprotection of Boc group is carried out with HCl solution in dioxane.
  • the deprotection reaction can be carried out at a temperature from ⁇ 4° C. to about 50° C.
  • the reaction is carried out at a temperature from 0° C. to about 25° C. or to room temperature.
  • the deprotection of Boc group is carried out at room temperature.
  • compounds prepared by the methods described herein include:
  • the releasable fusogenic lipids of Formula (I) include:
  • nanoparticle compositions containing a releasable fusogenic lipid of Formula (I) for the delivery of nucleic acids are provided.
  • the nanoparticle composition contains a cationic lipid, a releasable fusogenic lipid of Formula (I), and a PEG lipid.
  • the nanoparticle composition includes cholesterol.
  • the nanoparticle composition described herein may contain art-known fusogenic lipids (non-cationic lipids).
  • the nanoparticle composition containing a mixture of cationic lipids, a mixture of different fusogenic lipids and/or a mixture of different optional PEG lipids are also contemplated.
  • the nanoparticle composition contains a cationic lipid in a molar ratio ranging from about 10% to about 99.9% of the total lipid present in the nanoparticle composition.
  • the cationic lipid component can range from about 2% to about 60%, from about 5% to about 50%, from about 10% to about 45%, from about 15% to about 25%, or from about 30% to about 40% of the total lipid present in the nanoparticle composition.
  • the cationic lipid is present in amounts from about 15 to about 25% (i.e., 15, 17, 18, 20 or 25%) of the total lipid present in the nanoparticle composition.
  • the nanoparticle compositions contain the total fusogenic lipid (preferably releasable fusogenic lipid described herein), including cholesterol and/or noncholesterol-based fusogenic lipid, in a molar ratio of from about 20% to about 85%, from about 25% to about 85%, from about 60% to about 80% (e.g., 65, 75, 78, or 80%) of the total lipid present in the nanoparticle composition.
  • the total fusogenic/non-cationic lipid is about 80% of the total lipid present in the nanoparticle composition.
  • a noncholesterol-based fusogenic/non-cationic lipid is present in a molar ratio of from about 25 to about 78% (25, 35, 47, 60, or 78%), or from about 60 to about 78% of the total lipid present in the nanoparticle composition. In one embodiment, a noncholesterol-based fusogenic/non-cationic lipid is about 60% of the total lipid present in the nanoparticle composition.
  • the nanopartiele composition includes cholesterol in addition to non-cholesterol fusogenic lipid, in a molar ratio ranging from about 0% to about 60%, from about 10% to about 60%, or from about 20% to about 50% (e.g., 20, 30, 40 or 50%) of the total lipid present in the nanoparticle composition. In one embodiment, cholesterol is about 20% of the total lipid present in the nanoparticle composition.
  • the PEG-lipid contained in the nanoparticle composition ranges in a molar ratio of from about 0.5% to about 20%, from about 1.5% to about 18% of the total lipid present in the nanoparticle composition.
  • the PEG lipid is included in a molar ratio of from about 2% to about 10% (e.g., 2, 3, 4, 5, 6, 7, 8, 9 or 10%) of the total lipid.
  • the total PEG lipid is about 2% of the total lipid present in the nanoparticle composition.
  • the amount of a releasable fusogenic lipid contained in the nanoparticle composition shall be understood to mean the amount of a releasable fusogenic lipid described herein alone, or the sum of a releasable fusogenic lipid of Formula (I) and any additional art-known fusogenic lipids (either releasable or non-releasable) if present in the nanoparticle composition.
  • the nanoparticle composition described herein contains a releasable fusogenie of Formula (I).
  • the releasable fusogenic lipids of Formula (I) facilitate nucleic acids encapsulated in the nanoparticle release from endosomes and the nanoparticle after the nanoparticle enters cells.
  • the nanoparticle composition described herein may include additional art-known fusogenic lipids.
  • Additional suitable art-known fusogenic lipids useful in the nanoparticle composition include neutral fusogenic/noncationic lipids or anionic fusogenic lipids.
  • Neutral lipids include a lipid that exist either in an uncharged or neutral zwitter ionic form at a selected pH, preferably at physiological pH.
  • fusogenic lipids include diacylphosphatidylcholine, diacylphosphatidylethanolamine, ceramide, sphingomyelin, cephalin, cholesterol, cerebrosides and diacylglycerols.
  • Anionic lipids include a lipid that is negatively charged at physiological pH. These lipids include, but are not limited to, phosphatidylglycerol, cardiolipin, diacylphosphatidylserine, diacylphosphatidic acid, N-dodecanoyl phosphatidylethanolamines, N-succinyl phosphatidylethanolamines, N-glutarylphosphatidylethanolamines, lysylphosphatidylglycerols, palmitoyloleyolphosphatidylglycerol (POPG), and neutral lipids modified with other anionic modifying groups.
  • phosphatidylglycerol cardiolipin
  • diacylphosphatidylserine diacylphosphatidic acid
  • N-dodecanoyl phosphatidylethanolamines N-succinyl phosphatidylethanolamines
  • N-glutarylphosphatidylethanolamines
  • fusogenic lipids include amphipathic lipids generally having a hydrophobic moiety and a polar head group, and can form vesicles in aqueous solution.
  • Fusogenic lipids contemplated include naturally-occurring and synthetic phospholipids and related lipids.
  • non-cationic lipids are selected from among phospholipid and nonphosphous lipid related materials, such as lecithin; lysolecithin; diacylphosphatidylcholine; lysophosphatidylcholine; phosphatidylethanolamine; lysophosphatidylethanolamine; phosphatidylserine; phosphatidylinositol; sphingomyelin; cephalin; ceramide; cardiolipin; phosphatidic acid; phosphatidylglycerol; cerebrosides; dicetylphosphate;
  • phospholipid and nonphosphous lipid related materials such as lecithin; lysolecithin; diacylphosphatidylcholine; lysophosphatidylcholine; phosphatidylethanolamine; lysophosphatidylethanolamine; phosphatidylserine; phosphatidylinositol; sphingomyelin
  • DMG 1,2-dimyristoyl-sn-glycerol
  • DPG 1,2-dipalmitoyl-sn-glycerol
  • DSG 1,2-distearoyl-sn-glycerol
  • DLPA 1,2-dilauroyl-sn-glycero-3-phosphatidic acid
  • DMPA 1,2-dimyristoyl-sn-glycero-3-phosphatidic acid
  • DPPA 1,2-dipalmitoyl-sn-glycero-3-phosphatidic acid
  • DSPA 1,2-distearoyl-sn-glycero-3-phosphatidic acid
  • DAPC 1,2-diarachidoyl-sn-glycero-3-phosphocholine
  • DLPC 1,2-dilauroyl-sn-glycero-3-phosphocholine
  • DMPC 1,2-dimyristoyl-sn-glycero-3-phosphocholine
  • DPePC 1,2-dipalmitoyl-sn-glycero-3-ethylphosphocholine
  • DLPE 1,2-dilauroyl-sn-glycero-3-phosphoethanolamine
  • DLPG 1,2-dilauroyl-sn-glycero-3-phosphoglycerol
  • DMPG 1,2-dimyristoyl-sn-glycero-3-phosphoglycerol
  • DMP-sn-1-G 1,2-dimyristoyl-sn-glycero-3-phospho-sn-1-glycerol
  • DSPG 1,2-distearoyl-sn-glycero-3-phosphoglycerol
  • DSP-sn-1-G 1,2-distearoyl-sn-glycero-3-phospho-sn-1-glycerol
  • DPPS 1,2-dipalmitoyl-sn-glycero-3-phospho-L-serine
  • POPG 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol
  • DPhPE diphytanoylphosphatidylethanolamine
  • DOPG dioleoylphosphatidylglycerol
  • POPE palmitoyloleoylphosphatidylethanolamine
  • transDOPE 1,2-dielaidoyl-sn-glycero-3-phophoethanolamine
  • Noncationic lipids include sterols or steroid alcohols such as cholesterol.
  • Additional non-cationic lipids are, e.g., stearylamine, dodecylamine, hexadecylamine, acetylpalmitate, glycerolricinoleate, hexadecylstereate, isopropylmyristate, amphoteric acrylic polymers, triethanolaminelauryl sulfate, alkylarylsulfate polyethyloxylated fatty acid amides, and dioctadecyldimethyl ammonium bromide.
  • stearylamine dodecylamine, hexadecylamine, acetylpalmitate, glycerolricinoleate, hexadecylstereate, isopropylmyristate, amphoteric acrylic polymers, triethanolaminelauryl sulfate, alkylarylsulfate polyethyloxylated fatty acid amides, and
  • Anionic lipids contemplated include phosphatidylserine, phosphatidic acid, phosphatidylcholine, platelet-activation factor (PAF), phosphatidylethanolamine, phosphatidyl-DL-glycerol, phosphatidylinositol, phosphatidylinositol, cardiolipin, lysophosphatides, hydrogenated phospholipids, sphingoplipids, gangliosides, phytosphingosine, sphinganines, pharmaceutically acceptable salts and mixtures thereof.
  • PAF platelet-activation factor
  • Suitable noncationic lipids useful for the preparation of the nanoparticle composition described herein include diacylphosphatidylcholine (e.g., distearoylphosphatidylcholine, dioleoylphosphatidylcholine, dipalmitoylphosphatidylcholine and dilinoleoylphosphatidylcholine), diacylphosphatidylethanolamine (e.g., dioleoylphosphatidylethanolamine and palmitoyloleoylphosphatidylethanolamine), ceramide or sphingomyelin.
  • diacylphosphatidylcholine e.g., distearoylphosphatidylcholine, dioleoylphosphatidylcholine, dipalmitoylphosphatidylcholine and dilinoleoylphosphatidylcholine
  • diacylphosphatidylethanolamine e.g., dioleo
  • the acyl groups in these lipids are preferably fatty acids having saturated and unsaturated carbon chains such as linoyl, isostearyl, oleyl, elaidyl, petroselinyl, linolenyl, elacostearyl, arachidyl, myristoyl, palmitoyl, and lauroyl. More preferably the acyl groups are lauroyl, myristoyl, palmitoyl, stearoyl or oleoyl, more preferably fatty acids having saturated and unsaturated C 8 -C 30 (preferably C 10 -C 24 ) carbon chains.
  • C 8 -C 30 preferably C 10 -C 24
  • a variety of phosphatidylcholines useful in the nanoparticle composition described herein includes:
  • DDPC 1,2-didecanoyl-sn-glycero-3-phosphocholine
  • DMPC 1,2-dimyristoyl-sn-glycero-3-phosphocholine
  • 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC, C16:0, C16:0);
  • 1,2-dioleoyl-sn-glycero-3-phosphocholine DOPC, C18:1, C18:1;
  • DHA-PC 1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine
  • SMPC 1-stearoyl-2-myristoyl-sn-glycero-3-phosphocholine
  • POPC 1,2-stearoyl-oleoyl-sn-glycero-3-phosphoethanolamine
  • a variety of lysophosphatidylcholine useful in the nanoparticle composition described herein includes:
  • phosphatidylglycerols useful in the nanoparticle composition described herein are selected from among:
  • HSPG hydrogenated soybean phosphatidylglycerol
  • EPG egg phosphatidylgycerol
  • DMPG 1,2-dimyristoyl-sn-glycero-3-phosphoglycerol
  • DPPG 1,2-dipalmitoyl-sn-glycero-3-phosphoglycerol
  • DOPG 1,2-dioleoyl-sn-glycero-3-phosphoglycerol
  • POPG 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol
  • a variety of phosphatidic acids useful in the nanoparticle composition described herein includes:
  • DMPA 1,2-dimyristoyl-sn-glycero-3-phosphatidic acid
  • DPPA 1,2-dipalmitoyl-sn-glycero-3-phosphatidic acid
  • DSPA 1,2-distearoyl-sn-glycero-3-phosphatidic acid
  • a variety of phosphatidylethanolamines useful in the nanoparticle composition described herein includes:
  • HSPE hydrogenated soybean phosphatidylethanolamine
  • EPE non-hydrogenated egg phosphatidylethanolamine
  • DMPE 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine
  • DPPE 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine
  • DOPE 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine
  • POPE 1,2-dierucoyl-sn-glycero-3-phosphoethanolamine
  • a variety of phosphatidylserines useful in the nanoparticle composition described herein includes:
  • DMPS 1,2-dimyristoyl-sn-glycero-3-phospho-L-serine
  • DPPS 1,2-dipalmitoyl-sn-glycero-3-phospho-L-serine
  • DOPS 1,2-dioleoyl-sn-glycero-3-phospho-L-serine
  • POPS 1-palmitoyl-2-oleoyl-sn-3-phospho-L-serine
  • suitable neutral lipids useful for the preparation of the nanoparticle composition described herein include, for example,
  • DOPE dioleoylphosphatidylethanolamine
  • DSPE distearoylphosphatidylethanolamine
  • POPE palmitoyloleoylphosphatidylethanolamine
  • EPC egg phosphatidylcholine
  • DPPC dipalmitoylphosphatidylcholine
  • DSPC distearoylphosphatidylcholine
  • DOPC dioleoylphosphatidylcholine
  • POPC palmitoyloleoylphosphatidylcholine
  • DPPG dipalmitoylphosphatidylglycerol
  • DOPG dioleoylphosphatidylglycerol
  • DOPE-mal dioleoyl-phosphatidylethanolamine 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate
  • cholesterol pharmaceutically acceptable salts and mixtures thereof.
  • the nanoparticle composition described herein includes DSPC, EPC, DOPE, etc, and mixtures thereof.
  • the nanoparticle composition contains non-cationic lipids such as sterol.
  • the nanoparticle composition preferably contains cholesterol or analogs thereof, and more preferably cholesterol.
  • the nanoparticle composition described herein can include a cationic lipid.
  • Suitable lipids contemplated include, for example:
  • DOTMA N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride
  • DOTAP 1,2-bis(oleoyloxy)-3-3-(trimethylammonium)propane or N-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride
  • DMTAP 1,2-bis(dimyrstoyloxy)-3-3-(trimethylammonia)propane
  • BGTC 3 ⁇ -[N′,N′-diguanidinoethyl-aminoethane)carbamoyl cholesterol
  • 1,2-dialkenoyl-sn-glycero-3-ethylphosphocholines i.e., 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine, 1,2-distearoyl-sn-glycero-3-ethylphosphocholine and 1,2-dipalmitoyl-sn-glycero-3-ethylphosphocholine;
  • TTPS tetramethyltetrapalmitoyl spermine
  • TTOS tetramethyltetraoleyl spermine
  • TTLS tetramethlytetralauryl spermine
  • TTMS tetramethyltetramyristyl spermine
  • TMDOS tetramethyldioleyl spermine
  • DOGS 2,5-bis(3-aminopropylamino)-N-(2-(dioctadecylamino)-2-oxoethyl)pentanamide
  • N4-Spermine cholesteryl carbamate (GL-67);
  • DODMA dioctadecyldimethylammonium
  • DSDMA distearyldimethylammonium
  • DODAC N,N-dioleyl-N,N-dimethylammonium chloride
  • the cationic lipids would carry a net positive charge at a selected pH, such as pH ⁇ 13 (e.g. pH 6-12, pH 6-8).
  • a selected pH such as pH ⁇ 13 (e.g. pH 6-12, pH 6-8).
  • One preferred embodiment of the nanoparticle compositions includes the cationic lipids described herein having the structure:
  • R 1 is cholesterol or an analog thereof.
  • a nanoparticle composition includes the cationic lipid having the structure:
  • cationic lipids can be used: for example, LIPOFECTIN® (cationic liposomes containing DOTMA and DOPE, from GIBCO/BRL, Grand Island, N.Y., LISA); LIPOFECTAMINE® (cationic liposomes containing DOSPA and DOPE, from GIBCO/BRL, Grand Island, N.Y., USA); and TRANSFECTAM® (cationic liposomes containing DOGS from Promega Corp., Madison, Wis., USA).
  • LIPOFECTIN® cationic liposomes containing DOTMA and DOPE
  • LISA LIPOFECTAMINE®
  • TRANSFECTAM® cationic liposomes containing DOGS from Promega Corp., Madison, Wis., USA.
  • the nanoparticle composition described herein contains a PEG lipid.
  • the PEG lipids extend circulation of the nanoparticle described herein and prevent the premature excretion of the nanoparticles from the body.
  • the PEG lipids reduce the immunogenicity and enhance the stability of the nanoparticles.
  • the PEG lipids useful in the nanoparticle compositions include PEGylated forms of fusogenic/noncationic lipids.
  • the PEG lipids include, for example, PEG conjugated to diacylglycerol (PEG-DAG), PEG conjugated to diacylglycamides, PEG conjugated to dialkyloxypropyls (PEG-DAA), PEG conjugated to phospholipids such as PEG coupled to phosphatidylethanolamine (PEG-PE), PEG conjugated to ceramides (PEG-Cer), PEG conjugated to cholesterol derivatives (PEG-Chol) or mixtures thereof.
  • PEG-DAG diacylglycerol
  • PEG-DAA PEG conjugated to diacylglycamides
  • PEG conjugated to phospholipids such as PEG coupled to phosphatidylethanolamine (PEG-PE), PEG conjugated to ceramides (PEG
  • PEG is generally represented by the structure:
  • (n) is a positive integer from about 5 to about 2300, preferably from about 5 to about 460 so that the polymeric portion of PEG lipid has an average number molecular weight of from about 200 to about 100,000 daltons, preferably from about 200 to about 20,000 daltons.
  • (n) represents the degree of polymerization for the polymer, and is dependent on the molecular weight of the polymer.
  • the PEG is a polyethylene glycol with a number average molecular weight ranging from about 200 to about 20,000 daltons, more preferably from about 500 to about 10,000 daltons, yet more preferably from about 1,000 to about 5,000 daltons (i.e., about 1,500 to about 3,000 daltons). In one embodiment, the PEG has a molecular weight of about 2,000 daltons. In another embodiment, the PEG has a molecular weight of about 750 daltons.
  • polyethylene glycol (PEG) residue portion can be represented by the structure:
  • Y 71 and Y 73 are independently O, S, SO, SO 2 , NR 73 or a bond;
  • Y 72 is O, S, or NR 74 , preferably oxygen
  • R 71-74 are independently selected from among hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-19 branched alkyl, C 3-8 cycloalkyl, C 1-6 substituted alkyl, C 2-6 substituted alkenyl, C 2-6 substituted alkynyl, C 3-8 substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, C 1-6 heteroalkyl, substituted C 1-6 heteroalkyl, C 1-6 alkoxy, aryloxy, C 1-6 heteroalkoxy, heteroaryloxy, C 2-6 alkanoyl, arylcarbonyl, C 2-6 alkoxycarbonyl, aryloxycarbonyl, C 2-6 alkanoyloxy, arylcarbonyloxy, C 2-6 substituted alkanoyl, substituted arylcarbonyl, C 2-6 substituted alkanoyloxy, substituted arylcarbonyloxy
  • (a12) and (b12) are independently zero or positive integers, preferably zero or an integer from about 1 to about 6 (i.e., 1, 2, 3, 4, 5, 6), and more preferably 1 or 2; and
  • (n) is an integer from about 5 to about 2300, preferably from about 5 to about 460.
  • the terminal end of PEG can end with H, NH 2 , OH, CO 2 H, C 1-6 alkyl (e.g., methyl, ethyl, propyl), C 1-6 alkoxy, acyl or aryl.
  • the terminal hydroxyl group of PEG is substituted with a methoxy or methyl group.
  • the PEG employed in the PEG lipid is methoxy PEG.
  • the PEG may be directly conjugated to lipids or via a linker moiety.
  • the polymers for conjugation to a lipid structure are converted into a suitably activated polymer, using the activation techniques described in U.S. Pat. Nos. 5,122,614 and 5,808,096 and other techniques known in the art without undue experimentation.
  • activated PEGs useful for the preparation of a PEG lipid include, for example, methoxypolyethylene glycol-succinate, mPEG-NHS, methoxypolyethylene succinimidyl succinate, methoxypolyethyleneglycol-acetic acid (mPEG-CH 2 COOH), methoxypolyethylene glycol-amine (mPEG-NH 2 ), and methoxypolyethylene glycol-tresylate (mPEG-TRES).
  • polymers having terminal carboxylic acid groups can be used for the preparation of the PEG lipids.
  • Methods of preparing polymers having terminal carboxylic acids in high purity are described in U.S. patent application Ser. No. 11/328,662, the contents of which are incorporated herein by reference.
  • polymers having terminal amine groups can be employed to make the PEG-lipids.
  • the methods of preparing polymers containing terminal amines in high purity are described in U.S. patent application Ser. Nos. 11/508,507 and 11/537,172, the contents of each of which are incorporated by reference.
  • PEG and lipids can be bound via a linkage, i.e. a non-ester containing linker moiety or an ester containing linker moiety.
  • Suitable non-ester containing linkers include, but are not limited to, an amido linker moiety, an amino linker moiety, a carbonyl linker moiety, a carbamate linker moiety, a carbonate (OC( ⁇ O)O) linker moiety, a urea linker moiety, an ether linker moiety, a succinyl linker moiety, and combinations thereof.
  • Suitable ester linker moieties include, e.g., succinoyl, phosphate esters (—O—P( ⁇ O)(OH)—O—), sulfonate esters, and combinations thereof.
  • the nanoparticle composition described herein can include a polyethyleneglycol-diacylglycerol (PEG-DAG) or polyethylene-diacylglycamide.
  • PEG-DAG polyethyleneglycol-diacylglycerol
  • Suitable polyethyleneglycol-diacylglycerol or polyethyleneglycol-diacylglycamide conjugates include a dialkylglycerol or dialkylglycamide group having alkyl chain length independently containing from about C 4 to about C 30 (preferably from about C 8 to about C 24 ) saturated or unsaturated carbon atoms.
  • the dialkylglycerol or dialkylglycamide group can further include one or more substituted alkyl groups.
  • diacylglycerol used herein refers to a compound having two fatty acyl chains, R 111 and R 112 .
  • the R 111 and R 112 have the same or different carbon chain in length of about 4 to about 30 carbons (preferably about 8 to about 24) and are bonded to glycerol by ester linkages.
  • the acyl groups can be saturated or unsaturated with various degrees of unsaturation.
  • DAG has the general formula:
  • the PEG-diacylglycerol conjugate is a PEG-dilaurylglycerol (C12), a PEG-dimyristylglycerol (C14, DMG), a PEG-dipalmitoylglycerol (C16, DPG) or a PEG-distearylglycerol (C18, DSG).
  • a PEG-dilaurylglycerol C12
  • PEG-dimyristylglycerol C14, DMG
  • PEG-dipalmitoylglycerol C16, DPG
  • PEG-distearylglycerol C18, DSG
  • Examples of the PEG-diacylglycerol conjugate can be selected from among PEG-dilaurylglycerol (C12), PEG-dimyristylglycerol (C14), PEG-dipalmitoylglycerol (C16), PEG-disterylglycerol (C18).
  • Examples of the PEG-diacylglycamide conjugate includes PEG-dilaurylglycamide (C12), PEG-dimyristylglycamide (C14), PEG-dipalmitoyl-glycamide (C16), and PEG-disterylglycamide (C18).
  • the nanoparticle composition described herein can include a polyethyleneglycol-dialkyloxypropyl conjugates (PEG-DAA).
  • PEG-DAA polyethyleneglycol-dialkyloxypropyl conjugates
  • dialkyloxypropyl refers to a compound having two alkyl chains, R 111 and R 112 .
  • the R 111 and R 112 alkyl groups include the same or different carbon chain length between about 4 to about 30 carbons (preferably about 8 to about 24).
  • the alkyl groups can be saturated or have varying degrees of unsaturation.
  • Dialkyloxypropyls have the general formula:
  • R 111 and R 112 alkyl groups are the same or different alkyl groups having from about 4 to about 30 carbons (preferably about 8 to about 24).
  • the alkyl groups can be saturated or unsaturated. Suitable alkyl groups include, but are not limited to, lauryl (C12), myristyl (C14), palmityl (C16), stearyl (C18), oleoyl (C18) and icosyl (C20).
  • R 111 and R 112 are both the same, i.e., R 111 and R 112 are both myristyl (C14), both stearyl (C18) or both oleoyl (C18), etc.
  • R 111 and R 112 are different, i.e., R 111 is myristyl (C14) and R 112 is stearyl (C18).
  • the PEG-dialkylpropyl conjugates include the same R 111 and R 112 .
  • the nanoparticle composition described herein can include PEG conjugated to phosphatidylethanolamines (PEG-PE).
  • PEG-PE phosphatidylethanolamines
  • the phosphatidylethanolamines useful for the PEG lipid conjugation can contain saturated or unsaturated fatty acids with carbon chain lengths in the range of about 4 to about 30 carbons (preferably about 8 to about 24).
  • Suitable phosphatidylethanolamines include, but are not limited to dimyristoylphosphatidylethanolamine (DMPE), dipalmitoylphosphatidylethanolamine (DPPE), dioleoylphosphatidylethanolamine (DOPE) and distearoylphosphatidylethanolamine (DSPE).
  • the nanoparticle composition described herein can include PEG conjugated to ceramides (PEG-Cer). Ceramides have only one acyl group. Ceramides can have saturated or unsaturated fatty acids with carbon chain lengths in the range of about 4 to about 30 carbons (preferably about 8 to about 24).
  • the nanoparticle composition described herein can include PEG conjugated to cholesterol derivatives.
  • cholesterol derivative means any cholesterol analog containing a cholesterol structure with modification, i.e., substitutions and/or deletions thereof.
  • cholesterol derivative herein also includes steroid hormones and bile acids.
  • PEG lipids include N-(carbonyl-methoxypolyethyleneglycol)-1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine ( 2 kDa mPEG-DMPE or 51 kDa mPEG-DMPE); N-(carbonyl-methoxypolyethyleneglycol)-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine ( 2 kDa mPEG-DPPE or 5 kDa mPEG-DPPE); N-(carbonyl-methoxypolyethyleneglycol)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine ( 750 Da mPEG-DSPE, 2 kDa mPEG-DSPE, 5 kDa mPEG-DSPE); and pharmaceutically acceptable salts thereof (i.e., sodium salt) and mixtures thereof.
  • pharmaceutically acceptable salts thereof i.e., sodium salt
  • the nanoparticle composition described herein includes a PEG lipid having PEG-DAG or PEG-ceramide, wherein PEG has molecular weight from about 200 to about 20,000, preferably from about 500 to about 10,000, and more preferably from about 1,000 to about 5,000.
  • PEG-DAG and PEG-ceramide are provided in Table 1.
  • the nanoparticle composition described herein includes the PEG lipid selected from among PEG-DSPE, PEG-dipalmitoylglycamide (C16), PEG-Ceramide (C16), etc. and mixtures thereof.
  • PEG-DSPE PEG-dipalmitoylglycamide
  • C16 PEG-Ceramide
  • the structures of mPEG-DSPE, mPEG-dipalmitoylglycamide (C16), and mPEG-Ceramide (C16) are as follows:
  • (n) is an integer from about 5 to about 2300, preferably from about 5 to about 460.
  • (n) is about 45.
  • PAO-based polymers such as PEG
  • one or more effectively non-antigenic materials such as dextran, polyvinyl alcohols, carbohydrate-based polymers, hydroxypropylmethacrylamide (HPMA), polyalkylene oxides, and/or copolymers thereof can be used.
  • suitable polymers include, but are not limited to, polyvinylpyrrolidone, polymethyloxazoline, polyethyloxazoline, polyhydroxypropyl methacrylamide, polymethacrylamide and polydimethylacrylamide, polylactic acid, polyglycolic acid, and derivatized celluloses, such as hydroxymethylcellulose or hydroxyethylcellulose.
  • the nanoparticle described herein can include PEG lipids with a releasable linker such as ketal or imine.
  • PEG lipids with a releasable linker such as ketal or imine.
  • a releasable linker such as ketal or imine.
  • Such releasable PEG lipids allow nucleic acids (oligonucleotides) to dissociate from the delivery system after the delivery system enters the cells. Additional details of such releasable PEG lipids are also described in U.S. Provisional Patent Application Nos.
  • the nanoparticle compositions described herein can be used for delivering various nucleic acids into cells or tissues.
  • the nucleic acids include plasmids and oligonucleotides.
  • the nanoparticle compositions described herein are used for delivery of oligonucleotides.
  • nucleic acid or “nucleotide” apply to deoxyribonucleic acid (“DNA”), ribonucleic acid, (“RNA”) whether single-stranded or double-stranded, unless otherwise specified, and to any chemical modifications or analogs thereof, such as, locked nucleic acids (LNA).
  • LNA locked nucleic acids
  • oligonucleotide is generally a relatively short polynucleotide, e.g., ranging in size from about 2 to about 200 nucleotides, preferably from about 8 to about 50 nucleotides, more preferably from about 8 to about 30 nucleotides, and yet more preferably from about 8 to about 20 or from about 15 to about 28 in length.
  • the oligonucleotides according to the invention are generally synthetic nucleic acids, and are single stranded, unless otherwise specified.
  • the terms, “polynucleotide” and “polynucleic acid” may also be used synonymously herein.
  • oligonucleotides are not limited to a single species of oligonucleotide but, instead, are designed to work with a wide variety of such moieties, it being understood that linkers can attach to one or more of the 3′- or 5′-terminals, usually PO 4 or SO 4 groups of a nucleotide.
  • the nucleic acid molecules contemplated can include a phosphorothioate internucleotide linkage modification, sugar modification, nucleic acid base modification and/or phosphate backbone modification.
  • the oligonucleotides can contain natural phosphorodiester backbone or phosphorothioate backbone or any other modified backbone analogues such as LNA (Locked Nucleic Acid), PNA (nucleic acid with peptide backbone), CpG oligomers, and the like, such as those disclosed at Tides 2002, Oligonucleotide and Peptide Technology Conferences, May 6-8, 2002, Las Vegas, Nev. and Oligonucleotide & Peptide Technologies, 18th & 19th Nov. 2003, Hamburg, Germany, the contents of which are incorporated herein by reference.
  • LNA Locked Nucleic Acid
  • PNA nucleic acid with peptide backbone
  • CpG oligomers and the like, such as those disclosed at Tides 2002, Oligonucleotide and Peptide Technology Conferences, May 6-8, 2002, Las Vegas, Nev. and Oligonucleotide & Peptide Technologies, 18th & 19th Nov.
  • Modifications to the oligonucleotides contemplated by the invention include, for example, the addition or substitution of functional moieties that incorporate additional charge, polarizability, hydrogen bonding, electrostatic interaction, and functionality to an oligonucleotide.
  • modifications include, but are not limited to, 2′-position sugar modifications, 5-position pyrimidine modifications, 8-position purine modifications, modifications at exocyclic amines, substitution of 4-thiouridine, substitution of 5-bromo or 5-iodouracil, backbone modifications, methylations, base-pairing combinations such as the isobases isocytidine and isoguanidine, and analogous combinations.
  • Oligonucleotides contemplated within the scope of the present invention can also include 3′ and/or 5′ cap structure
  • cap structure shall be understood to mean chemical modifications, which have been incorporated at either terminus of the oligonucleotide.
  • the cap can be present at the 5′-terminus (5′-cap) or at the 3′-terminus (3′-cap) or can be present on both termini.
  • a non-limiting example of the 5′-cap includes inverted abasic residue (moiety), 4′,5′-methylene nucleotide; 1-(beta-D-erythrofuranosyl) nucleotide, 4′-thio nucleotide, carbocyclic nucleotide; 1,5-anhydrohexitol nucleotide; L-nucleotides; alpha-nucleotides; modified base nucleotide; phosphorodithioate linkage; threo-pentofuranosyl nucleotide; acyclic 3′,4′-seco nucleotide; acyclic 3,4-dihydroxybutyl nucleotide; acyclic 3,5-dihydroxypentyl nucleotide; 3′-3′-inverted nucleotide moiety; 3′-3′-inverted abasic moiety; 3′-2′-inverted nucleotide moiety; 3′
  • the 3′-cap can include for example 4′,5′-methylene nucleotide; 1-(beta-D-erythrofuranosyl) nucleotide; 4′-thio nucleotide, carbocyclic nucleotide; 5′-aminoalkyl phosphate; 1,3-diamino-2-propyl phosphate; 3-aminopropyl phosphate; 6-aminohexyl phosphate; 1,2-aminododecyl phosphate; hydroxypropyl phosphate; 1,5-anhydrohexitol nucleotide; L-nucleotide; alpha-nucleotide; modified base nucleotide; phosphorodithioate; threo-pentofuranosyl nucleotide; acyclic 3′,4′-seco nucleotide; 3,
  • nucleoside analogs have the structure:
  • antisense refers to nucleotide sequences which are complementary to a specific DNA or RNA sequence that encodes a gene product or that encodes a control sequence.
  • antisense strand is used in reference to a nucleic acid strand that is complementary to the “sense” strand.
  • the sense strand of a DNA molecule is the strand that encodes polypeptides and/or other gene products.
  • the sense strand serves as a template for synthesis of a messenger RNA (“mRNA”) transcript (an antisense strand) which, in turn, directs synthesis of any encoded gene product.
  • mRNA messenger RNA
  • Antisense nucleic acid molecules may be produced by any art-known methods, including synthesis.
  • this transcribed strand combines with natural sequences produced by the cell to form duplexes. These duplexes then block either the further transcription of the mRNA or its translation.
  • the designations “negative” or ( ⁇ ) are also art-known to refer to the antisense strand, and “positive” or (+) are also art-known to refer to the sense strand.
  • “complementary” shall be understood to mean that a nucleic acid sequence forms hydrogen bond(s) with another nucleic acid sequence.
  • a percent complementarity indicates the percentage of contiguous residues in a nucleic acid molecule which can form hydrogen bonds, i.e., Watson-Crick base pairing, with a second nucleic acid sequence, i.e., 5, 6, 7, 8, 9, 10 out of 10 being 50%, 60%, 70%, 80%, 90%, and 100% complementary.
  • Perfectly complementary means that all the contiguous residues of a nucleic acid sequence form hydrogen bonds with the same number of contiguous residues in a second nucleic acid sequence.
  • the nucleic acids (such as one or more same or different oligonucleotides or oligonucloetide derivatives) useful in the nanoparticle described herein can include from about 5 to about 1000 nucleic acids, and preferably relatively short polynucleotides, e.g., ranging in size preferably from about 8 to about 50 nucleotides in length (e.g., about 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30).
  • useful nucleic acids encapsulated within the nanoparticle described herein include oligonucleotides and oligodeoxynucleotides with natural phosphorodiester backbone or phosphorothioate backbone or any other modified backbone analogues such as:
  • PNA nucleic acid with peptide backbone
  • siRNA short interfering RNA
  • microRNA miRNA
  • PNA nucleic acid with peptide backbone
  • PMO phosphorodiamidate morpholino oligonucleotides
  • decoy ODN double stranded oligonucleotide
  • RNAi catalytic RNA sequence
  • spiegelmers L-conformational oligonucleotides
  • oligonucleotides can optionally include any suitable art-known nucleotide analogs and derivatives, including those listed by Table 2, below:
  • the target oligonucleotides encapsulated in the nanoparticles include, for example, but are not limited to, oncogenes, pro-angiogenesis pathway genes, pro-cell proliferation pathway genes, viral infectious agent genes, and pro-inflammatory pathway genes.
  • the oligonucleotide encapsulated within the nanoparticle described herein is involved in targeting tumor cells or downregulating a gene or protein expression associated with tumor cells and/or the resistance of tumor cells to anticancer therapeutics.
  • antisense oligonucleotides for downregulating any art-known cellular proteins associated with cancer e.g., BCL-2 can be used for the present invention. See U.S. patent application Ser. No. 10/822,205 filed Apr. 9, 2004, the contents of which are incorporated by reference herein.
  • a non-limiting list of preferred therapeutic oligonucleotides includes antisense bcl-2 oligonucleotides, antisense HIF-1 ⁇ oligonucleotides, antisense survivin oligonucleotides, antisense ErbB3 oligonucleotides, antisense PIK3CA oligonucleotides, antisense HSP27 oligonucleotides, antisense androgen receptor oligonucleotides, antisense Gli2 oligonucleotides, and antisense beta-catenin oligonucleotides.
  • the oligonucleotides according to the invention described herein include phosphorothioate backbone and LNA.
  • the oligonucleotide can be, for example, antisense survivin LNA, antisense ErbB3 LNA, or antisense HIF1- ⁇ LNA.
  • the oligonucleotide can be, for example, an oligonucleotide that has the same or substantially similar nucleotide sequence as does Genasense® (a/k/a oblimersen sodium, produced by Genta Inc., Berkeley Heights, N.J.).
  • Genasense® is an 18-mer phosphorothioate antisense oligonucleotide (SEQ ID NO: 4), that is complementary to the first six codons of the initiating sequence of the human bcl-2 mRNA (human bcl-2 mRNA is art-known, and is described, e.g., as SEQ ID NO: 19 in U.S. Pat. No. 6,414,134, incorporated by reference herein).
  • Genasense phosphorothioate antisense oligonucleotide: (SEQ ID NO: 4)
  • Lower case letters represent DNA units, bold upper case letters represent LNA such as ⁇ -D-oxy-LNA units. All cytosine bases in the LNA monomers are 5-methylcytosine. Subscript “s” represents phosphorothioate linkage.
  • LNA includes 2′-O, 4′-C methylene bicyclonudeotide as shown below:
  • the nanoparticle described herein can include oligonucleotides releasably linked to an endosomal release-promoting group.
  • the endosomal release-promoting groups such as histidine-rich peptides can disrupt the endosomal membrane, thereby facilitating cytoplasmic delivery of therapeutic agents. Histidine-rich peptides enhance endosomal release of oligonucleotides to the cytoplasm. Then, the intracellularly released oligonucleotides can translocate to the nucleus. Additional details of oligonucleotide-histidine rich peptide conjugates are described in U.S. Provisional Patent Application Ser. Nos.
  • the nanoparticle compositions described herein further include a targeting ligand for a specific cell or tissue type.
  • the targeting group can be attached to any component of a nanoparticle composition (preferably, fusogenic lipids and PEG-lipids) using a linker molecule, such as an amide, amido, carbonyl, ester, peptide, disulphide, silane, nucleoside, abasic nucleoside, polyether, polyamine, polyamide, peptide, carbohydrate, lipid, polyhydrocarbon, phosphate ester, phosphoramidate, thiophosphate, alkylphosphate, maleimidyl linker or photolabile linker. Any known techniques in the art can be used for conjugating a targeting group to any component of the nanoparticle composition without undue experimentation.
  • targeting agents can be attached to the polymeric portion of PEG lipids to guide the nanoparticles to the target area in vivo.
  • the targeted delivery of the nanoparticle described herein enhances the cellular uptake of the nanoparticles encapsulating therapeutic nucleic acids, thereby improving the therapeutic efficacies.
  • some cell penetrating peptides can be replaced with a variety of targeting peptides for targeted delivery to the tumor site.
  • the targeting moiety such as a single chain antibody (SCA) or single-chain antigen-binding antibody, monoclonal antibody, cell adhesion peptides such as RGD peptides and Selectin, cell penetrating peptides (CPPs) such as TAT, Penetratin and (Arg) 9 , receptor ligands, targeting carbohydrate molecules or lectins allows nanoparticles to be specifically directed to targeted regions.
  • SCA single chain antibody
  • CPPs cell penetrating peptides
  • Preferred targeting moieties include single-chain antibodies (SCAB) or single-chain variable fragments of antibodies (sFv).
  • SCAB single-chain antibodies
  • sFv single-chain variable fragments of antibodies
  • the SCA contains domains of antibodies which can bind or recognize specific molecules of targeting tumor cells.
  • a SCA conjugated to a PEG-lipid can reduce antigenicity and increase the half life of the SCA in the bloodstream.
  • single chain antibody SCA
  • single-chain antigen-binding molecule or antibody SCA
  • single-chain Fv single-chain Fv
  • Single chain antibody SCA
  • single-chain Fvs can and have been constructed in several ways. A description of the theory and production of single-chain antigen-binding proteins is found in commonly assigned U.S. patent application Ser. No. 10/915,069 and U.S. Pat. No. 6,824,782, the contents of each of which are incorporated by reference herein.
  • SCA or Fv domains can be selected among monoclonal antibodies known by their abbreviations in the literature as 26-10, MOPC 315, 741F8, 520C9, McPC 603, D1.3, murine phOx, human phOx, RFL3.8 sTCR, 1A6, Se155-4,18-2-3,4-4-20,7A4-1, B6.2, CC49,3C2,2c, MA-15C5/K 12 G O , Ox, etc. (see, Huston, J. S. et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988); Huston, J. S.
  • a non-limiting list of targeting groups includes vascular endothelial cell growth factor, FGF2, somatostatin and somatostatin analogs, transferrin, melanotropin, ApoE and ApoE peptides, von Willebrand's Factor and von Willebrand's Factor peptides, adenoviral fiber protein and adenoviral fiber protein peptides, PD1 and PD1 peptides, EGF and EGF peptides, RGD peptides, folate, anisamide, etc.
  • Other optional targeting agents appreciated by artisans in the art can be also employed in the nanoparticles described herein.
  • the targeting agents useful for the compounds described herein include single chain antibody (SCA), RGD peptides, selectin, TAT, penetratin, (Arg) 9 , folic acid, anisamide, etc., and some of the preferred structures of these agents are:
  • C-TAT (SEQ ID NO: 17) CYGRKKRRQRRR; C-(Arg) 9 : (SEQ ID NO: 18) CRRRRRRRRR;
  • RGD can be linear or cyclic:
  • Anisamide is p-MeO-Ph-C( ⁇ O)OH.
  • Arg 9 can include a cysteine for conjugating such as CRRRRRRRRR and TAT can add an additional cysteine at the end of the peptide such as CYGRKKRRQRRRC.
  • the targeting group include sugars and carbohydrates such as galactose, galactosamine, and N-acetyl galactosamine; hormones such as estrogen, testosterone, progesterone, glucocortisone, adrenaline, insulin, glucagon, cortisol, vitamin D, thyroid hormone, retinoic acid, and growth hormones; growth factors such as VEGF, EGF, NGF, and PDGF; neurotransmitters such as GABA, Glutamate, acetylcholine; NOGO; inostitol triphosphate; epinephrine; norepinephrine; Nitric Oxide, peptides, vitamins such as folate and pyridoxine, drugs, antibodies and any other molecule that can interact with a cell surface receptor in vivo or in vitro.
  • hormones such as estrogen, testosterone, progesterone, glucocortisone, adrenaline, insulin, glucagon, cortisol, vitamin D, thyroid hormone, retinoic acid,
  • nanoparticle described herein can be prepared by any art-known process without undue experimentation.
  • the nanoparticle can be prepared by providing nucleic acids such as oligonucleotides in an aqueous solution (or an aqueous solution without nucleic acids for comparison study) in a first reservoir, providing an organic lipid solution containing the nanoparticle composition described herein in a second reservoir, and mixing the aqueous solution with the organic lipid solution such that the organic lipid solution mixes with the aqueous solution to produce nanoparticles encapsulating the nucleic acids. Details of the process are described in U.S. Patent Publication No. 2004/0142025, the contents of which are incorporated herein by reference.
  • the nanoparticles described herein can be prepared by using any methods known in the art including, e.g., a detergent dialysis method or a modified reverse-phase method which utilizes organic solvents to provide a single phase during mixing the components.
  • a detergent dialysis method nucleic acids (i.e., siRNA) are contacted with a detergent solution of cationic lipids to form a coated nucleic acid complex.
  • the cationic lipids and nucleic acids such as oligonucleotides are combined to produce a charge ratio of from about 1:20 to about 20:1, preferably in a ratio of from about 1:5 to about 5:1, and more preferably in a ratio of from about 1:2 to about 2:1.
  • the cationic lipids and nucleic acids such as oligonucleotides are combined to produce a charge ratio of from about 1:1 to about 20:1, from about 1:1 to about 12:1, and more preferably in a ratio of from about 2:1 to about 6:1.
  • the nitrogen to phoshpate (N/P) ratio of the nanoparticle composition ranges from about 2:1 to about 5:1, (i.e., 2.5:1).
  • the nanoparticle described herein can be prepared by using a dual pump system.
  • the process includes providing an aqueous solution containing nucleic acids in a first reservoir and a lipid solution containing the nanoparticle composition described in a second reservoir.
  • the two solutions are mixed by using a dual pump system to provide nanoparticles.
  • the resulting mixed solution is subsequently diluted with an aqueous buffer and the nanoparticles formed can be purified and/or isolated by dialysis.
  • the nanoparticles can be further processed to be sterilized by filtering through a 0.22 ⁇ m filter.
  • the nanoparticles containing nucleic acids range from about 5 to about 300 nm in diameter.
  • the nanoparticles have a median diameter of less than about 150 nm (e.g., about 50-150 nm), more preferably a diameter of less than about 100 nm, by the measurement using the Dynamic Light Scattering technique (DLS).
  • a majority of the nanoparticles have a median diameter of about 30 to 100 nm (e.g., 59.5, 66, 68, 76, 80, 93, 96 nm), preferably about 60 to about 95 nm.
  • TEM may provide a median diameter number decreased by half, as compared to the DLS technique.
  • the nanoparticles of the present invention are substantially uniform in size as shown by polydispersity.
  • the nanoparticles can be sized by any methods known in the art.
  • the size can be controlled as desired by artisans.
  • the sizing may be conducted in order to achieve a desired size range and relatively narrow distribution of nanoparticle sizes.
  • Several techniques are available for sizing the nanoparticles to a desired size. See, for example, U.S. Pat. No. 4,737,323, the contents of which are incorporated herein by reference.
  • the present invention provides methods for preparing serum-stable nanoparticles such that nucleic acids (e.g., LNA or siRNA) are encapsulated in a lipid multi-lamellar structure (i.e. a lipid bilayer) and are protected from degradation.
  • nucleic acids e.g., LNA or siRNA
  • the nanoparticles described herein are stable in an aqueous solution. Nucleic acids included in the nanoparticles are protected from nucleases present in the body fluid.
  • nanoparticles prepared according to the present invention are preferably neutral or positively-charged at physiological pH.
  • the nanoparticle or nanoparticle complex prepared using the nanoparticle composition described herein includes: (i) a cationic lipid; (ii) a fusogenic lipid including a compound of Formula (I); (iii) a PEG-lipid and (iv) nucleic acids such as an oligonucleotide.
  • the nanoparticle composition includes a mixture of a cationic lipid, a compound of Formula (I) optionally with a diacylphosphatidylethanolamine, a PEG conjugated to phosphatidylethanolamine (PEG-PE), and cholesterol;
  • a cationic lipid a compound of Formula (I) optionally with a diacylphosphatidylcholine, a PEG conjugated to phosphatidylethanolamine (PEG-PE), and cholesterol;
  • a cationic lipid a compound of Formula (I) optionally with a diacylphosphatidylethanolamine, a PEG conjugated to ceramide (PEG-Cer), and cholesterol; and
  • a cationic lipid a compound of Formula (I) optionally with a diacylphosphatidylethanolamine, a PEG conjugated to phosphatidylethanolamine (PEG-PE), a PEG conjugated to ceramide (PEG-Cer), and cholesterol.
  • PEG-PE PEG conjugated to phosphatidylethanolamine
  • PEG-Cer PEG conjugated to ceramide
  • Nanoparticle compositions can be prepared by modifying compositions containing art-known cationic lipid(s).
  • Nanoparticle compositions containing a compound of Formula (I) can be modified by adding art-known cationic lipids. See art-known compositions described in Table IV of US Patent Application Publication No. 2008/0020058, the contents of which are incorporated herein by reference.
  • the molar ratio of cationic lipid 1:compound 10:cholesterol:PEG-DSPE:C16mPEG-Ceramide in the nanoparticle is in a molar ratio of about 18%:60%:20%:1%:1%, respectively.
  • the nanoparticle contains cationic lipid 1, compound 10, cholesterol and C16mPEG-Ceramide in a molar ratio of about 17%:60%:20%:3% of the total lipid present in the nanoparticle composition. (Sample No. 7)
  • the cationic lipid contained in the compositions has the structure:
  • these nanoparticle compositions contain a releasable polymeric lipid having the structure:
  • the polymer portion of the PEG lipid has a number average weight of about 2,000 daltons.
  • the molar ratio as used herein refers to the amount relative to the total lipid present in the nanoparticle composition.
  • the nanoparticles described herein can be employed in the treatment for preventing, inhibiting, reducing or treating any trait, disease or condition that is related to or responds to the levels of target gene expression in a cell or tissue, alone or in combination with other therapies.
  • the methods include administering the nanoparticles described herein to a mammal in need thereof.
  • One aspect of the present invention provides methods of introducing or delivering therapeutic agents such as nucleic acids/oligonucleotides into a mammalian cell in vivo and/or in vitro.
  • the method according to the present invention includes contacting a cell with the compounds described herein.
  • the delivery can be made in vivo as part of a suitable pharmaceutical composition or directly to the cells in an ex vivo or in vitro environment.
  • the present invention is useful for introducing oligonucleotides to a mammal.
  • the compounds described herein can be administered to a mammal, preferably human.
  • the present invention preferably provides methods of inhibiting, or downregulating (or modulating) gene expression in mammalian cells or tissues.
  • the downregulation or inhibition of gene expression can be achieved in vivo, ex vivo and/or in vitro.
  • the methods include contacting human cells or tissues with nanoparticles encapsulating nucleic acids or administering the nanoparticles to a mammal in need thereof.
  • successful inhibition or down-regulation of gene expression such as in mRNA or protein levels shall be deemed to occur when at least about 10%, preferably at least about 20% or higher (e.g., at least about 25%, 30%, 40%, 50%, 60%) is realized in vivo, ex vivo or in vitro when compared to that observed in the absence of the nanoparticles described herein.
  • inhibiting or “downregulating” shall be understood to mean that the expression of a target gene, or level of RNAs or equivalent RNAs encoding one or more protein subunits, or activity of one or more protein subunits is reduced when compared to that observed in the absence of the nanoparticles described herein.
  • a target gene includes, for example, but is not limited to, oncogenes, pro-angiogenesis pathway genes, pro-cell proliferation pathway genes, viral infectious agent genes, and pro-inflammatory pathway genes.
  • cancer cells or tissues for example, brain, breast, colorectal, gastric, lung, mouth, pancreatic, prostate, skin or cervical cancer cells.
  • the cancer cells or tissues can be from one or more of the following: solid tumors, lymphomas, small cell lung cancer, acute lymphocytic leukemia (ALL), pancreatic cancer, glioblastoma, ovarian cancer, gastric cancer, breast cancer, colorectal cancer, prostate cancer, cervical cancer, brain tumors, KB cancer, lung cancer, colon cancer, epidermal cancer, etc.
  • the nanoparticles according to the methods described herein include, for example, antisense bcl-2 oligonucleotides, antisense HIF-1 ⁇ oligonucleotides, antisense survivin oligonucleotides, antisense ErbB3 oligonucleotides, antisense PIK3CA oligonucleotides, antisense HSP27 oligonucleotides, antisense androgen receptor oligonucleotides, antisense Gli2 oligonucleotides, and antisense beta-catenin oligonucleotides.
  • the nanoparticles can include oligonucleotides (SEQ ID NO: 1, SEQ ID NOs 2 and 3, SEQ ID NO:3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, and SEQ ID NO: 16 in which each nucleic acid is a naturally occurring or modified nucleic acid) can be used.
  • the therapy contemplated herein uses nucleic acids encapsulated in the aforementioned nanoparticle.
  • therapeutic nucleotides containing eight or more consecutive antisense nucleotides can be employed in the treatment.
  • the methods include administering an effective amount of a pharmaceutical composition containing a nanoparticle described herein to a patient in need thereof.
  • the efficacy of the methods would depend upon efficacy of the nucleic acids for the condition being treated.
  • the present invention provides methods of treatment for various medical conditions in mammals.
  • the methods include administering, to the mammal in need of such treatment, an effective amount of a nanoparticle containing encapsulated therapeutic nucleic acids.
  • the nanoparticles described herein are useful for, among other things, treating diseases such as (but not limited to) cancer, inflammatory disease, and autoimmune disease.
  • a patient having a malignancy or cancer comprising administering an effective amount of a pharmaceutical composition containing the nanoparticle described herein to a patient in need thereof.
  • the cancer being treated can be one or more of the following: solid tumors, lymphomas, small cell lung cancer, acute lymphocytic leukemia (ALL), pancreatic cancer, glioblastoma, ovarian cancer, gastric cancers, colorectal cancer, prostate cancer, cervical cancer, brain tumors, KB cancer, lung cancer, colon cancer, epidermal cancer, etc.
  • the nanoparticles are useful for treating neoplastic disease, reducing tumor burden, preventing metastasis of neoplasms and preventing recurrences of tumor/neoplastic growths in mammals by downregulating gene expression of a target gene.
  • the nanoparticles are useful in the treatment of metastatic disease (i.e. cancer with metastasis into the liver).
  • the present invention provides methods of inhibiting the growth or proliferation of cancer cells in vivo or in vitro.
  • the methods include contacting cancer cells with the nanoparticle described herein.
  • the present invention provides methods of inhibiting the growth of cancer in vivo or in vitro wherein the cells express ErbB3 gene.
  • the present invention provides a means to deliver nucleic acids (e.g., antisense ErbB3 LNA oligonucleotides) inside a cancer cell where it can bind to ErbB3 mRNA, e.g., in the nucleus.
  • nucleic acids e.g., antisense ErbB3 LNA oligonucleotides
  • the methods introduce oligonucleotides (e.g. antisense oligonucleotides including LNA) to cancer cells and reduce target gene (e.g., survivin, HIF-1 ⁇ or ErbB3) expression in the cancer cells or tissues.
  • the present invention provides methods of modulating apoptosis in cancer cells.
  • methods of increasing the sensitivity of cancer cells or tissues to chemotherapeutic agents in vivo or in vitro are also provided.
  • the methods include introducing the compounds described herein to tumor cells to reduce gene expression such as ErbB3 gene and contacting the tumor cells with an amount of at least one anticancer agent (e.g., a chemotherapeutic agent) sufficient to kill a portion of the tumor cells.
  • a chemotherapeutic agent e.g., a chemotherapeutic agent
  • an anticancer/chemotherapeutic agent can be used in combination, simultaneously or sequentially, with the compounds described herein.
  • the compounds described herein can be administered prior to, or concurrently with, the anticancer agent, or after the administration of the anticancer agent.
  • the nanoparticles described herein can be administered prior to, during, or after treatment of the chemotherapeutic agent.
  • Still further aspects include combining the compound of the present invention described herein with other anticancer therapies for synergistic or additive benefit.
  • the nanoparticle composition described herein can be used to deliver a pharmaceutically active agent, preferably having a negative charge or a neutral charge to a mammal.
  • the nanoparticle encapsulating pharmaceutically active agents/compounds can be administered to a mammal in need thereof.
  • the pharmaceutically active agents/compounds include small molecular weight molecules.
  • the pharmaceutically active agents have a molecular weight of less than about 1,500 daltons (i.e., less than 1,000 daltons).
  • the compounds described herein can be used to deliver nucleic acids, a pharmaceutically active agent, or in combination thereof.
  • the nanoparticle associated with the treatment can contain a mixture of one or more therapeutic nucleic acids (either the same or different, for example, the same or different oligonucleotides), and/or one or more pharmaceutically active agents for synergistic application.
  • compositions/formulations including the nanoparticles described herein may be formulated in conjunction with one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen, i.e., whether local or systemic treatment is treated.
  • Suitable forms depend upon the use or the route of entry, for example oral, transdermal, or injection. Factors for considerations known in the art for preparing proper formulations include, but are not limited to, toxicity and any disadvantages that would prevent the composition or formulation from exerting its effect.
  • Topical administration includes, without limitation, administration via the epidermal, transdermal, ophthalmic routes; including via mucous membranes, e.g., including vaginal and rectal delivery.
  • Parenteral administration including intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion, is also contemplated.
  • the nanoparticles containing therapeutic oligonucleotides are administered intravenously (i.v.) or intraperitoneally (i.p.). Parenteral routes are preferred in many aspects of the invention.
  • the nanoparticles of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as physiological saline buffer or polar solvents including, without limitation, a pyrrolidone or dimethylsulfoxide.
  • physiologically compatible buffers such as physiological saline buffer or polar solvents including, without limitation, a pyrrolidone or dimethylsulfoxide.
  • the nanoparticles may also be formulated for bolus injection or for continuous infusion.
  • Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers.
  • Useful compositions include, without limitation, suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain adjuncts such as suspending, stabilizing and/or dispersing agents.
  • Pharmaceutical compositions for parenteral administration include aqueous solutions of a water soluble form.
  • Aqueous injection suspensions may contain substances that modulate the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.
  • the suspension may also contain suitable stabilizers and/or agents that increase the concentration of the nanoparticles in the solution.
  • the nanoparticles may be in powder form for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water, before use.
  • the nanoparticles described herein can be formulated by combining the nanoparticles with pharmaceutically acceptable carriers well-known in the art.
  • Such carriers enable the nanoparticles of the invention to be formulated as tablets, pills, lozenges, dragees, capsules, liquids, gels, syrups, pastes, slurries, solutions, suspensions, concentrated solutions and suspensions for diluting in the drinking water of a patient, premixes for dilution in the feed of a patient, and the like, for oral ingestion by a patient.
  • compositions for oral use can be made using a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding other suitable auxiliaries if desired, to obtain tablets or dragee cores.
  • Useful excipients are, in particular, fillers such as sugars (for example, lactose, sucrose, mannitol, or sorbitol), cellulose preparations such as maize starch, wheat starch, rice starch and potato starch and other materials such as gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP).
  • disintegrating agents may be added, such as cross-linked polyvinyl pyrrolidone, agar, or alginic acid. A salt such as sodium alginate may also be used.
  • the nanoparticles of the present invention can conveniently be delivered in the form of an aerosol spray using a pressurized pack or a nebulizer and a suitable propellant.
  • the nanoparticles may also be formulated in rectal compositions such as suppositories or retention enemas, using, e.g., conventional suppository bases such as cocoa butter or other glycerides.
  • the nanoparticles may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection.
  • a nanoparticle of this invention may be formulated for this route of administration with suitable polymeric or hydrophobic materials (for instance, in an emulsion with a pharmacologically acceptable oil), with ion exchange resins, or as a sparingly soluble derivative such as, without limitation, a sparingly soluble salt.
  • the nanoparticles may be delivered using a sustained-release system, such as semi-permeable matrices of solid hydrophobic polymers containing the nanoparticles.
  • sustained-release materials have been established and are well known by those skilled in the art.
  • antioxidants and suspending agents can be used in the pharmaceutical compositions of the nanoparticles described herein.
  • the therapeutically effective amount can be estimated initially from in vitro assays. Then, the dosage can be formulated for use in animal models so as to achieve a circulating concentration range that includes the effective dosage. Such information can then be used to more accurately determine dosages useful in patients.
  • the amount of the pharmaceutical composition that is administered will depend upon the potency of the nucleic acids included therein. Generally, the amount of the nanoparticles containing nucleic acids used in the treatment is that amount which effectively achieves the desired therapeutic result in mammals. Naturally, the dosages of the various nanoparticles will vary somewhat depending upon the nucleic acids (or pharmaceutically active agents) encapsulated therein (e.g., oligonucleotides). In addition, the dosage, of course, can vary depending upon the dosage form and route of administration.
  • nucleic acids encapsulated in the nanoparticles described herein can be administered in amounts ranging from about 0.1 to about 1 g/kg/week, preferably from about 1 to about 500 mg/kg and more preferably from 1 to about 100 mg/kg (i.e., from about 3 to about 90 mg/kg/dose).
  • an amount of from about 1 mg to about 100 mg/kg/dose can be used in the treatment depending on potency of the nucleic acids.
  • Dosage unit forms generally range from about 1 mg to about 60 mg of an active agent, oligonucleotides.
  • the treatment of the present invention includes administering the nanoparticles described herein in an amount of from about 1 to about 60 mg/kg/dose (from about 25 to 60 mg/kg/dose, from, about 3 to about 20 mg/kg/dose), such as 60, 45, 35, 30, 25, 15, 5 or 3 mg/kg/dose (either in a single or multiple dose regime) to a mammal.
  • the nanoparticles described herein can be administered introvenously in an amount of 5, 25, 30, or 60 mg/kg/dose at q3d ⁇ 9.
  • the treatment protocol includes administering an antisense oligonucleotide in an amount of from about 4 to about 18 mg/kg/dose weekly, or about 4 to about 9.5 mg/kg/dose weekly (e.g., about 8 mg/kg/dose weekly for 3 weeks in a six week cycle).
  • the delivery of the oligonucleotide encapsulated within the nanoparticles described herein includes contacting a concentration of oligonucleotides of from about 0.1 to about 1000 ⁇ M, preferably from about 10 to about 1500 ⁇ M (i.e. from about 10 to about 1000 ⁇ M, from about 30 to about 1000 ⁇ M) with tumor cells or tissues in vivo, ex vivo or in vitro.
  • compositions may be administered once daily or divided into multiple doses which can be given as part of a multi-week treatment protocol.
  • the precise dose will depend on the stage and severity of the condition, the susceptibility of the disease such as tumor to the nucleic acids, and the individual characteristics of the patient being treated, as will be appreciated by one of ordinary skill in the art.
  • the dosage amount mentioned is based on the amount of oligonucleotide molecules rather than the amount of nanoparticles administered.
  • the treatment will be given for one or more days until the desired clinical result is obtained.
  • the exact amount, frequency and period of administration of the nanoparticles encapsulating therapeutic nucleic acids (or pharmaceutically active agents) will vary, of course, depending upon the sex, age and medical condition of the patent as well as the severity of the disease as determined by the attending clinician.
  • Still further aspects include combining the nanoparticles of the present invention described herein with other anticancer therapies for synergistic or additive benefit.
  • Oligo-1 (SEQ ID NO: 1) 5′- m CT m CAatccatgg m CAGc-3′
  • Oligo-2 (SEQ ID NO: 6) 5′-TAGcctgtcactt m CT m C-3′
  • LNA Locked nucleic acid oligonucleotide
  • BACC (2-[N,N′-di(2-guanidiniumpropyl)]aminoethyl-cholesteryl-carbonate), Chol (cholesterol), DIEA (diisopropylethylamine), DMAP (4-N,N-dimethylamino-pyridine), DOPE (L- ⁇ -dioleoyl phosphatidylethanolamine, Avanti Polar Lipids, USA or NOF, Japan), DLS (Dynamic Light Scattering), DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine) (NOF, Japan), DSPE-PEG (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-(polyethylene glycol)2000 ammonium salt or sodium salt, Avanti Polar Lipids, USA and NOF,
  • FAM 6-carboxyfluorescein
  • FBS fetal bovine serum
  • GAPDH glycosylase dehydrogenase
  • DMEM Dulbecco's Modified Eagle's Medium
  • MEM Modified Eagle's Medium
  • TEAA tetraethylammonium acetate
  • TFA trifluoroacetic acid
  • RT-qPCR reverse transcription-quantitative polymerase chain reaction
  • the reaction mixtures and the purity of intermediates and final products are monitored by a Beckman Coulter System Gold® HPLC instrument. It employs a ZORBAX® 300SB C8 reversed phase column (150 ⁇ 4.6 mm) or a Phenomenex Jupiter® 300A C18 reversed phase column (150 ⁇ 4.6 mm) with a 168 Diode Array UV Detector, using a gradient of 10-90% of acetonitrile in 0.05% TFA at a flow rate of 1 mL/minute or a gradient of 25-35% acetonitrile in 50 mM TEAA buffer at a flow rate of 1 mL/minute.
  • the anion exchange chromatography was run on AKTA explorer 100A from GE healthcare (Amersham Biosciences) using Poros 50HQ strong anion exchange resin from Applied Biosystems packed in an AP-Empty glass column from Waters. Desalting was achieved by using HiPrep 26/10 desalting columns from Amersham Biosciences. (for PEG-Oligo)
  • the cells are maintained in complete medium (F-12K or DMEM, supplemented with 10% FBS).
  • F-12K or DMEM supplemented with 10% FBS.
  • a 12 well plate containing 2.5 ⁇ 10 5 cells in each well is incubated overnight at 37° C.
  • Cells are washed once with Opti-MEM® and 400 ⁇ L of Opti-MEM® is added per each well.
  • a solution of nanoparticle or Lipofectamine2000® containing oligonucleotide is added to each well.
  • the cells is incubated for 4 hours, followed by addition of 600 ⁇ L of media per well, and incubation for 24 hours.
  • the intracellular mRNA levels of the target gene such as human survivin, and a housekeeping gene, such as GAPDH are quantitated by RT-qPCR.
  • the expression levels of mRNA are normalized.
  • RNA is prepared using RNAqueous Kit® (Ambion) following the manufacturer's instruction. The RNA concentrations are determined by OD 260 nm using Nanodrop.
  • the reaction is conducted in a PCR thermocycler at 25° C. for 10 minutes, 37° C. for 120 minutes, 85° C. for 5 seconds and then stored at 4° C.
  • Real-time PCR is conducted with the program of 50° C-2 minutes, 95° C.-10 minutes, and 95° C.-15 seconds/60° C.-1 minute for 40 cycles.
  • 1 ⁇ L of cDNA is used in a final volume of 30 ⁇ L.
  • H-Dap-(Boc)-OMe HCl (5 g, 19.63 mmol) was treated with 2M HCl in 1,4-dioxane (130 mL) for 30 minutes at room temperature. The solvents were removed in vacuo at 30-35° C. The residue was re-suspended in diethyl ether and filtered. Isolated solids were dried in vacuo over P 2 O 5 to yield 3.4 g (90%) of product: 113 C NMR (DMSO-d 6 ) ⁇ 38.95, 49.99, 53.53, 66.37, 166.77.
  • reaction mixture was diluted with 200 mL of reagent grade of DCM and washed with 1N HCl (3 ⁇ 80 mL) and 0.5% aqueous NaHCO 3 (3 ⁇ 80 mL). The resulting organic layer was separated, dried over anhydrous magnesium sulfate and concentrated in vacuo at 30° C.
  • reaction mixture was diluted with 500 mL of DCM, washed with 0.2 N HCl (3 ⁇ 500 mL) and water (3 ⁇ 500 mL), and dried over anhydrous magnesium sulfate. The solvent was removed in vacuo at 35° C.
  • nanoparticle compositions encapsulating various nucleic acids such as LNA-containing oligonucleotides are prepared.
  • cationic lipid 1, compound 10, Chol, DSPE-PEG and C 16 mPEG-Ceramide are mixed at a molar ratio of 18:60:20:1:1 in 10 mL of 90% ethanol (total lipid 30 pinole).
  • LNA oligonucleotides (0.4 ⁇ mole) are dissolved in 10 mL of 20 mM Tris buffer (pH 7.4-7.6).
  • the two solutions After being heated to 37° C., the two solutions are mixed together through a duel syringe pump and the mixed solution is subsequently diluted with 20 mL of 20 mM Tris buffer (300 mM NaCl, pH 7.4-7.6).
  • the mixture is incubated at 37° C. for 30 minutes and dialyzed in 10 mM PBS buffer (138 mM NaCl, 2.7 mM KCl, pH 7.4).
  • Stable particles are obtained after the removal of ethanol from the mixture by dialysis.
  • the nanoparticle solution is concentrated by centrifugation.
  • the nanoparticle solution is transferred into a 15 mL centrifugal filter device (Amicon Ultra-15, Millipore, USA).
  • Centrifuge speed is at 3,000 rpm and temperature is at 4° C. during centrifugation.
  • the concentrated suspension is collected after a given time and is sterilized by filtration through a 0.22 ⁇ m syringe filter (Millex-GV, Millipore, USA).
  • the diameter and polydispersity of nanoparticle are measured at 25° in water (Sigma) as a medium on a Plus 90 Particle Size Analyzer Dynamic Light Scattering Instrument (Brookhaven, N.Y.).
  • Encapsulation efficiency of LNA oligonucleotides is determined by UV-VIS (Agilent 8453).
  • the background UV-vis spectrum is obtained by scanning solution, which is a mixed solution composed of PBS buffer saline (250 ⁇ L), methanol (625 ⁇ L) and chloroform (250 ⁇ L).
  • scanning solution is a mixed solution composed of PBS buffer saline (250 ⁇ L), methanol (625 ⁇ L) and chloroform (250 ⁇ L).
  • methanol (625 ⁇ L) and chloroform (250 ⁇ L) are added to PBS buffer saline nanoparticle suspension (250 ⁇ L). After mixing, a clear solution is obtained and this solution is sonicated for 2 minutes before measuring absorbance at 260 nm.
  • the encapsulated nucleic acid concentration and loading efficiency is calculated according to equations (1) and (2):
  • C en is the nucleic acid (i.e., LNA oligonucleotide) concentration encapsulated in nanoparticle suspension after purification
  • C initial is the initial nucleic acid (LNA oligonucleotide) concentration before the formation of the nanoparticle suspension.
  • Nanoparticle stability is defined as their capability to retain the structural integrity in PBS buffer at 4° C. over time. The colloidal stability of nanoparticles is evaluated by monitoring changes in the mean diameter over time. Nanoparticles prepared by Sample No. NP1 in Table 6 are dispersed in 10 mM PBS buffer (138 mM NaCl, 2.7 mM KCl, pH 7.4) and stored at 4° C. At a given time point, about 20-50 ⁇ L of the nanoparticle suspension is taken and diluted with pure water up to 2 mL. The sizes of nanoparticles are measured by DLS at 25° C.
  • LNA oligonucleotide Oligo-2 The efficiency of cellular uptake of nucleic acids (LNA oligonucleotide Oligo-2) encapsulated in the nanoparticle described herein is evaluated in human cancer cells such as prostate cancer cells (15PC3 cell line).
  • Nanoparticles of Sample NP2 are prepared using the method described in Example 16.
  • LNA oligonucleotides (Oligo-2) are labeled with FAM for fluorescent microscopy studies.
  • the nanoparticles are evaluated in the 15PC3 cell line.
  • the cells are maintained in a complete medium (DMEM, supplemented with 10% FBS), A 12 well plate containing 2.5 ⁇ 10 5 cells in each well is incubated overnight at 37° C.
  • the cells are washed once with Opti-MEM and 400 mL of Opti-MEM is added to each well.
  • the cells are treated with a nanoparticle solution of Sample No. NP2 (200 nM) encapsulating nucleic acids (FAM-modified Oligo 2) or a solution of free nucleic acids without the nanoparticles (naked FAM-modified Oligo 2) as a control.
  • the cells are incubated for 24 hours at 37° C.
  • the cells are washed with PBS five times, and then stained with 300 mL of Hoechst solution (2 mg/mL) per well for 30 minutes, followed by washing with PBS 5 times.
  • the cells are fixed with pre-cooled ( ⁇ 20° C.) 70% EtOH at ⁇ 20° C. for 20 minutes.
  • the cells are inspected under fluorescent microscope to evaluate the efficiency of cellular uptake of nucleic acids encapsulated within the nanoparticle described herein.
  • the efficacy of the nanoparticles described herein is evaluated in a variety of cancer cells, for example, human epideram cancer cells (A431), human gastric cancer cells (N87), human lung cancer cells (A549, HCC827, or H1581), human prostate cancer cells (15PC3, LNCaP, PC3, CWR22, DU145), human breast cancer cells (MCF7, SKBR3), colon cancer cells (SW480), pancreatic cancer cells (BxPC3), and melanoma (518A2).
  • the cells are treated with one of the following: nanoparticles encapsulating antisense ErbB3 oligonucleotides (Sample NP1), or empty placebo nanoparticles (Sample No. NP3).
  • the in vitro efficacy of each of the nanoparticles on downregulation of ErbB3 expression is measured by the procedures described in Example 3.
  • the in vivo efficacy of nanoparticles described herein is evaluated in human prostate cancer xenografted mice.
  • the 15PC3 human prostate tumors are established in nude mice by subcutaneous injection of 5 ⁇ 10 6 cells/mouse into the right auxiliary flank. When tumors reach the average volume of 100 mm 3 , the mice are randomly grouped 5 mice per group. The mice of each group are treated with nanoparticle encapsulating antisense ErbB3 oligonucleotides (Sample NP1) or corresponding naked oligonucleotides (Oligo 2).
  • the nanoparticles are given intravenously (i.v.) at 15 mg/kg/dose, 5 mg/kg/dose, 1 mg/kg/dose, or 0.5 mg/kg/dose at q3d ⁇ 4 (or q3d ⁇ 10).
  • the dosage amount is based on the amount of oligonucleotides in the nanoparticles.
  • the naked oligonucleotides are given intraperitoneally (i.p.) at 30 mg/kg/dose or intravenously at 25 mg/kg/dose or 45 mg/kg/dose at q3d ⁇ 4 for 12 days.
  • the mice are sacrificed twenty four hours after the final dose. Plasma samples are collected from the mice and stored at ⁇ 20° C. Tumor and liver samples are also collected from the mice. The samples are analyzed for mRNA KD in the tumors and livers. The survival of the animals is observed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
US13/129,546 2008-11-17 2009-11-17 Releasable fusogenic lipids for nucleic acids delivery systems Abandoned US20110223257A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/129,546 US20110223257A1 (en) 2008-11-17 2009-11-17 Releasable fusogenic lipids for nucleic acids delivery systems

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11537808P 2008-11-17 2008-11-17
US13/129,546 US20110223257A1 (en) 2008-11-17 2009-11-17 Releasable fusogenic lipids for nucleic acids delivery systems
PCT/US2009/064730 WO2010057160A1 (en) 2008-11-17 2009-11-17 Releasable fusogenic lipids for nucleic acids delivery systems

Publications (1)

Publication Number Publication Date
US20110223257A1 true US20110223257A1 (en) 2011-09-15

Family

ID=42170408

Family Applications (1)

Application Number Title Priority Date Filing Date
US13/129,546 Abandoned US20110223257A1 (en) 2008-11-17 2009-11-17 Releasable fusogenic lipids for nucleic acids delivery systems

Country Status (7)

Country Link
US (1) US20110223257A1 (zh)
EP (1) EP2355799A4 (zh)
JP (1) JP2012509273A (zh)
CN (1) CN102215820A (zh)
CA (1) CA2742846A1 (zh)
TW (1) TW201021852A (zh)
WO (1) WO2010057160A1 (zh)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140309406A1 (en) * 2011-03-29 2014-10-16 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
WO2015139025A1 (en) * 2014-03-14 2015-09-17 The Regents Of The University Of California Tco conjugates and methods for delivery of therapeutic agents
US9376500B2 (en) 2009-06-03 2016-06-28 Immunogen, Inc. Conjugation methods
US9789204B2 (en) 2005-08-24 2017-10-17 Immunogen, Inc. Process for preparing purified drug conjugates
US9796690B2 (en) 2014-05-28 2017-10-24 Bayer Cropscience Aktiengesellschaft Process for preparing dihydroisoxazole derivatives
US10035817B2 (en) 2012-10-04 2018-07-31 Immunogen, Inc. Method of purifying cell-binding agent-cytotoxic agent conjugates with a PVDF membrane
US10130711B2 (en) 2013-06-19 2018-11-20 The Regents Of The University Of California Chemical structures for localized delivery of therapeutic agents
WO2019090359A1 (en) * 2017-11-06 2019-05-09 Nitto Denko Corporation Fusogenic compounds for delivery of biologically active molecules
US10358680B2 (en) * 2012-09-11 2019-07-23 Duke University Nano-plasmonic molecular probes for plasmonics coupling interference
US10828373B2 (en) 2015-09-10 2020-11-10 Tambo, Inc. Bioorthogonal compositions
US11213593B2 (en) 2014-11-21 2022-01-04 Northwestern University Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
US11253600B2 (en) 2017-04-07 2022-02-22 Tambo, Inc. Bioorthogonal compositions
EP2791160B1 (en) 2011-12-16 2022-03-02 ModernaTX, Inc. Modified mrna compositions
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
US11433131B2 (en) 2017-05-11 2022-09-06 Northwestern University Adoptive cell therapy using spherical nucleic acids (SNAs)
US11633503B2 (en) 2009-01-08 2023-04-25 Northwestern University Delivery of oligonucleotide-functionalized nanoparticles
US11690920B2 (en) 2017-07-13 2023-07-04 Northwestern University General and direct method for preparing oligonucleotide-functionalized metal-organic framework nanoparticles
RU2808990C2 (ru) * 2017-11-06 2023-12-05 Нитто Денко Корпорейшн Фузогенные соединения для доставки биологически активных молекул
US11883535B2 (en) 2013-12-03 2024-01-30 Northwestern University Liposomal particles, methods of making same and uses thereof
US11957788B2 (en) 2014-06-04 2024-04-16 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012509272A (ja) * 2008-11-17 2012-04-19 エンゾン ファーマシューティカルズ，インコーポレーテッド 核酸送達系のための放出性カチオン脂質
EP2575764B1 (en) * 2010-06-03 2017-04-19 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
PL3135301T3 (pl) 2010-06-22 2018-11-30 Onxeo Zoptymalizowany system dostarczania in vivo z czynnikami andosomolitycznymi koniugatów kwasów nukleinowych
EP2527440A1 (en) 2011-05-27 2012-11-28 Institut Curie Cancer treatment by combining DNA molecules mimicking double strand breaks with hyperthermia
DE21212055T1 (de) 2011-12-07 2022-08-04 Alnylam Pharmaceuticals, Inc. Biologisch abbaubare lipide zur freisetzung von wirkstoffen
CN107951861B (zh) * 2016-10-17 2020-12-01 南京绿叶制药有限公司 一种脂质纳米粒膜材料组合物
CN112587504B (zh) * 2016-10-17 2022-10-18 南京绿叶制药有限公司 一种抑制bcl-2的反义寡聚核酸的脂质纳米粒及其制备方法
US10383952B2 (en) * 2016-12-21 2019-08-20 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153434A (en) * 1998-05-12 2000-11-28 University Of Florida Methods for the intracellular delivery of substances
US20030077829A1 (en) * 2001-04-30 2003-04-24 Protiva Biotherapeutics Inc.. Lipid-based formulations
US6670461B1 (en) * 1997-09-12 2003-12-30 Exiqon A/S Oligonucleotide analogues
US6841537B1 (en) * 1998-04-22 2005-01-11 Protiva Biotherapeutics Inc. Combination therapy using nucleic acids and conventional drugs
US20050175682A1 (en) * 2003-09-15 2005-08-11 Protiva Biotherapeutics, Inc. Polyethyleneglycol-modified lipid compounds and uses thereof
US20050222064A1 (en) * 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
US20060051405A1 (en) * 2004-07-19 2006-03-09 Protiva Biotherapeutics, Inc. Compositions for the delivery of therapeutic agents and uses thereof
US20060240554A1 (en) * 2005-02-14 2006-10-26 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
US20070042983A1 (en) * 2001-05-18 2007-02-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20070219134A1 (en) * 2006-02-01 2007-09-20 The Burnham Institute For Medical Research Lymphatic zip codes in tumors and pre-malignant lesions
US20070293449A1 (en) * 2006-06-20 2007-12-20 Nastech Pharmaceutical Company Inc. Compositions and methods for delivery of double-stranded rna
US20080020058A1 (en) * 2005-02-14 2008-01-24 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
US7341738B2 (en) * 1997-05-14 2008-03-11 The University Of British Columbia Lipid-encapsulated polyanionic nucleic acid
US20080281044A1 (en) * 2006-08-18 2008-11-13 Monahan Sean D Endosomolytic Modified Poly(Alcohol) and Poly(Amine) Polymers

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945408A (en) * 1996-03-06 1999-08-31 G.D. Searle & Co. Hydroxyanidino derivatives useful as nitric oxide synthase inhibitors
US7015349B2 (en) * 2003-03-26 2006-03-21 The Gillette Company Reduction of hair growth
AU2004305016A1 (en) * 2003-12-10 2005-07-07 Nitromed, Inc. Nitric oxide releasing pyruvate compounds, compositions and methods of use
JP2008530021A (ja) * 2005-02-08 2008-08-07 アイディー バイオメディカル コーポレイション オブ ケベック シー．オー．ビー． アズ グラクソスミスクライン バイオロジカルズ ノース アメリカ 医薬組成物
US20070014842A1 (en) * 2005-03-07 2007-01-18 Denis Martin Pharmaceutical liposomal compositions
US20080255234A1 (en) * 2007-04-11 2008-10-16 Zinpro Corporation Rumen protected lysine
CN101674853B (zh) * 2007-05-04 2013-03-27 玛瑞纳生物技术有限公司 氨基酸脂质及其用途

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7341738B2 (en) * 1997-05-14 2008-03-11 The University Of British Columbia Lipid-encapsulated polyanionic nucleic acid
US6670461B1 (en) * 1997-09-12 2003-12-30 Exiqon A/S Oligonucleotide analogues
US6841537B1 (en) * 1998-04-22 2005-01-11 Protiva Biotherapeutics Inc. Combination therapy using nucleic acids and conventional drugs
US6153434A (en) * 1998-05-12 2000-11-28 University Of Florida Methods for the intracellular delivery of substances
US6169078B1 (en) * 1998-05-12 2001-01-02 University Of Florida Materials and methods for the intracellular delivery of substances
US20030077829A1 (en) * 2001-04-30 2003-04-24 Protiva Biotherapeutics Inc.. Lipid-based formulations
US20070042983A1 (en) * 2001-05-18 2007-02-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20050222064A1 (en) * 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
US20050175682A1 (en) * 2003-09-15 2005-08-11 Protiva Biotherapeutics, Inc. Polyethyleneglycol-modified lipid compounds and uses thereof
US20060051405A1 (en) * 2004-07-19 2006-03-09 Protiva Biotherapeutics, Inc. Compositions for the delivery of therapeutic agents and uses thereof
US20060240554A1 (en) * 2005-02-14 2006-10-26 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
US20080020058A1 (en) * 2005-02-14 2008-01-24 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
US20070219134A1 (en) * 2006-02-01 2007-09-20 The Burnham Institute For Medical Research Lymphatic zip codes in tumors and pre-malignant lesions
US20070293449A1 (en) * 2006-06-20 2007-12-20 Nastech Pharmaceutical Company Inc. Compositions and methods for delivery of double-stranded rna
US20080281044A1 (en) * 2006-08-18 2008-11-13 Monahan Sean D Endosomolytic Modified Poly(Alcohol) and Poly(Amine) Polymers

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11471536B2 (en) 2005-08-24 2022-10-18 Immunogen, Inc. Process for preparing purified drug conjugates
US9789204B2 (en) 2005-08-24 2017-10-17 Immunogen, Inc. Process for preparing purified drug conjugates
US11633503B2 (en) 2009-01-08 2023-04-25 Northwestern University Delivery of oligonucleotide-functionalized nanoparticles
US10233257B2 (en) 2009-06-03 2019-03-19 Immunogen, Inc. Methods for preparing antibody-drug conjugates
US10815309B2 (en) 2009-06-03 2020-10-27 Immunogen, Inc. Methods for preparing antibody-drug conjugates
US9376500B2 (en) 2009-06-03 2016-06-28 Immunogen, Inc. Conjugation methods
US11498979B2 (en) 2009-06-03 2022-11-15 Immunogen, Inc. Methods for preparing a purified maytansinoid conjugate in a solution
US9771432B2 (en) 2009-06-03 2017-09-26 Immunogen, Inc. Conjugation methods
US11090390B2 (en) 2011-03-29 2021-08-17 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
US20140309406A1 (en) * 2011-03-29 2014-10-16 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
US9914748B2 (en) 2011-03-29 2018-03-13 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
US9428543B2 (en) * 2011-03-29 2016-08-30 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
US10435432B2 (en) 2011-03-29 2019-10-08 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
US11744900B2 (en) 2011-03-29 2023-09-05 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
EP2791160B1 (en) 2011-12-16 2022-03-02 ModernaTX, Inc. Modified mrna compositions
US10358680B2 (en) * 2012-09-11 2019-07-23 Duke University Nano-plasmonic molecular probes for plasmonics coupling interference
US10035817B2 (en) 2012-10-04 2018-07-31 Immunogen, Inc. Method of purifying cell-binding agent-cytotoxic agent conjugates with a PVDF membrane
US10130711B2 (en) 2013-06-19 2018-11-20 The Regents Of The University Of California Chemical structures for localized delivery of therapeutic agents
US10953098B2 (en) 2013-06-19 2021-03-23 The Regents Of The University Of California Chemical structures for localized delivery of therapeutic agents
US11883535B2 (en) 2013-12-03 2024-01-30 Northwestern University Liposomal particles, methods of making same and uses thereof
US10342882B2 (en) 2014-03-14 2019-07-09 The Regents Of The University Of California TCO conjugates and methods for delivery of therapeutic agents
US10806807B2 (en) 2014-03-14 2020-10-20 The Regents Of The University Of California TCO conjugates and methods for delivery of therapeutic agents
US10130723B2 (en) 2014-03-14 2018-11-20 The Regents Of The University Of California TCO conjugates and methods for delivery of therapeutic agents
CN106659796A (zh) * 2014-03-14 2017-05-10 加利福尼亚大学董事会 Tco缀合物和治疗剂递送方法
WO2015139025A1 (en) * 2014-03-14 2015-09-17 The Regents Of The University Of California Tco conjugates and methods for delivery of therapeutic agents
US9796690B2 (en) 2014-05-28 2017-10-24 Bayer Cropscience Aktiengesellschaft Process for preparing dihydroisoxazole derivatives
US11957788B2 (en) 2014-06-04 2024-04-16 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
US11213593B2 (en) 2014-11-21 2022-01-04 Northwestern University Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
US10828373B2 (en) 2015-09-10 2020-11-10 Tambo, Inc. Bioorthogonal compositions
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
US11253600B2 (en) 2017-04-07 2022-02-22 Tambo, Inc. Bioorthogonal compositions
US11433131B2 (en) 2017-05-11 2022-09-06 Northwestern University Adoptive cell therapy using spherical nucleic acids (SNAs)
US11690920B2 (en) 2017-07-13 2023-07-04 Northwestern University General and direct method for preparing oligonucleotide-functionalized metal-organic framework nanoparticles
US11413243B2 (en) 2017-11-06 2022-08-16 Nitto Denko Corporation Fusogenic compounds for delivery of biologically active molecules
AU2018359904B2 (en) * 2017-11-06 2023-02-23 Nitto Denko Corporation Fusogenic compounds for delivery of biologically active molecules
EP3706729A4 (en) * 2017-11-06 2021-12-01 Nitto Denko Corporation FUSOGENIC COMPOUNDS FOR THE DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES
JP2021502346A (ja) * 2017-11-06 2021-01-28 日東電工株式会社 生物学的活性分子を送達するための融合性化合物
RU2808990C2 (ru) * 2017-11-06 2023-12-05 Нитто Денко Корпорейшн Фузогенные соединения для доставки биологически активных молекул
JP7423518B2 (ja) 2017-11-06 2024-01-29 日東電工株式会社 生物学的活性分子を送達するための融合性化合物
CN111386105A (zh) * 2017-11-06 2020-07-07 日东电工株式会社 用于递送生物活性分子的膜融合化合物
WO2019090359A1 (en) * 2017-11-06 2019-05-09 Nitto Denko Corporation Fusogenic compounds for delivery of biologically active molecules

Also Published As

Publication number Publication date
WO2010057160A1 (en) 2010-05-20
TW201021852A (en) 2010-06-16
EP2355799A1 (en) 2011-08-17
EP2355799A4 (en) 2012-09-05
JP2012509273A (ja) 2012-04-19
WO2010057160A9 (en) 2011-05-05
CN102215820A (zh) 2011-10-12
CA2742846A1 (en) 2010-05-20

Similar Documents

Publication Publication Date Title
US20110223257A1 (en) Releasable fusogenic lipids for nucleic acids delivery systems
US20110305770A1 (en) Releasable polymeric lipids for nucleic acids delivery system
US20110229581A1 (en) Releasable cationic lipids for nucleic acids delivery systems
US20110305769A1 (en) Branched cationic lipids for nucleic acids delivery system
US20110111044A1 (en) Nanoparticle compositions for nucleic acids delivery system
US20190151461A1 (en) Process for formulating an anionic agent
KR101762466B1 (ko) 지질, 지질 조성물 및 이의 사용 방법
JP2018115164A (ja) アミン陽イオン性脂質およびその使用
US20120264810A1 (en) Compositions and methods for enhancing cellular uptake and intracellular delivery of lipid particles
US20110230420A1 (en) Releasable conjugates for nucleic acids delivery systems
US9233971B2 (en) Lipomacrocycles and uses thereof
CN117658848A (zh) 递送治疗剂的脂质化合物及其应用

Legal Events

Date Code Title Description
AS Assignment

Owner name: ENZON PHARMACEUTICALS, INC., NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZHAO, HONG;YAN, WEILI;SHI, LIANJUN;AND OTHERS;SIGNING DATES FROM 20091212 TO 20100129;REEL/FRAME:023878/0960

AS Assignment

Owner name: ENZON PHARMACEUTICALS, INC., NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZHAO, HONG;YAN, WEILI;SHI, LIANJUN;AND OTHERS;SIGNING DATES FROM 20110601 TO 20111011;REEL/FRAME:027092/0561

AS Assignment

Owner name: BELROSE PHARMA, INC., NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ENZON PHARMACEUTICALS, INC.;REEL/FRAME:030982/0692

Effective date: 20130430

AS Assignment

Owner name: BELROSE PHARMA INC., NEW JERSEY

Free format text: CHANGE OF ADDRESS;ASSIGNOR:BELROSE PHARMA INC.;REEL/FRAME:032152/0906

Effective date: 20140203

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION